Entities

Joyeeta Das is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. Her technology and entrepreneurship career includes Cisco, founding SuperPitch and leading SamundraOceans, alongside data and AI advisory work and support for women innovators. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Malika Arshad supports Future Planet Capital’s fundraising, investor engagement and investment work. She previously worked in investment banking at Credit Suisse.

Marcel Gehrung is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His background combines a Cambridge doctorate in healthcare machine learning with co-founding and leading Cyted, developing diagnostic technology for digestive disease. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Massimo Noro is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. He represents STFC in UKI2S and leads business development at Daresbury, following global industrial research at Unilever. His scientific training includes a UCLA physical-chemistry doctorate. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Nat Wei is published as Advisory Board Member with Future Planet Capital. He is a member of the House of Lords with experience in government advisory work and parliamentary business groups. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Nicholas Barsby is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His published background includes Army logistics, defence-science advisory work and programme management. His DASA chief-of-staff responsibilities span budgeting, performance and communications. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Nick Bassett is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His published career includes BBSRC innovation leadership, InnovateUK investor-partnership development, diagnostic-device work and co-founding an immunohistochemistry business. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Paul Abberley is published as Chair of Investment Governance Board with Future Planet Capital. His professional experience includes senior institutional asset-management and investment leadership at ABNAmro, Aviva and CharlesStanley. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Peter Hamley is the founder and CEO of Scripta Therapeutics, an Oxford techbio company developing transcription-factor-directed therapeutics for neurodegenerative diseases.

Priya Guha is published as Investment Governance Board Member with Future Planet Capital. Her experience spans technology leadership and public oversight, including UKRI, Reach and TechSheCan; she received an MBE in2021. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Robin Chase is published as Advisory Board Member with Future Planet Capital. She co-founded and previously led Zipcar, bringing operating experience in shared transport. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Ruth Elliot is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. She trained in accountancy at Deloitte and subsequently held senior public-sector finance roles, including deputy CFO at UKRI and finance/corporate-services leadership at UKAEA. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Sugata Mitra is published as Advisory Board Member with Future Planet Capital. He is known for educational-technology research and the Hole in the Wall project and received the TED Prize in2013. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Tony Raven is published as UKI2S Chair of Board and Consultation Committee within the UK Innovation & Science Seed Fund ecosystem. His career combines research, entrepreneurship and university technology transfer. He led Cambridge Enterprise for tenyears until2021 and helped establish Cambridge Innovation Capital and the TenU university-commercialisation network. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Christophe Romeyer is published by Sofilaro Calen as Fund Director, Development and Succession. The current public directory identifies this role but does not supply a longer career biography.

Manuel Potier is published by Sofilaro Calen as Fund Director, Development and Succession. The current public directory identifies this role but does not supply a longer career biography.

Patrice Roch is published by Sofilaro Calen as Managing Director. The current public directory identifies this role but does not supply a longer career biography.

Abi Wye is published as Network Director with Future Planet Capital. Her experience spans government, NGOs and private-client networks; she previously served as political private secretary to DavidCameron. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Alex Leigh is published as Managing Director, National with Future Planet Capital. His background combines mechatronics engineering, an MBA and venture/private-equity investment in deep technology. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Alex Shadbolt is published as Investment Manager & Impact Lead with Future Planet Capital. He works on investment management and the firm’s impact framework, including investment decisions, internal processes and portfolio monitoring. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Andrew Carpenter is published as General Counsel with Future Planet Capital. His professional background is corporate law, including partner positions at international law firms and transactions in Britain and abroad. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Andrew Muir is published as Investment Director with Future Planet Capital. His career combines chemistry research at Oxford, industry work at Zeneca and a US startup, and venture investment at NESTA. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Andy Bard is published as Portfolio Manager with Future Planet Capital. His accounting training was at KPMG, followed by work managing and realising RBS equity investments; he studied accounting and finance at Leeds. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Daniel Gaize is published as Investment Associate with Future Planet Capital. He works on the Midlands Engine Investment Fund and brings experience from LGPS Central, family offices and Standard Life Investments; he holds the CAIA designation. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Darren Heffernan is published as Director of Finance & Operations with Future Planet Capital. His accounting and finance career includes Asian financial reporting at an international bank and large transformation programmes. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

David Knox is published as Director with Future Planet Capital. He founded and leads Lazarus after more than20years in financial-market advisory, including research leadership and executive-committee membership at J.P.Morgan Cazenove. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Denis Martins is published by Sofilaro Calen as President of platform (public title; statutory SAS president is Sofilaro Gestion). The current public directory identifies this role but does not supply a longer career biography.

Douglas Hansen-Luke founded Future Planet Capital in 2015 and is its executive chairman. His background combines international finance, entrepreneurship and research into institutional investment.

Duncan Johnson is Northern Gritstone’s founding chief executive and previously led Caledonia Private Capital.

Ed Phillips is Future Planet Capital’s global managing director and a founding team member. He invests through its global, Blue Ocean and Challenge Response strategies and has a molecular genetics research background.

Emily Thompson is a Northern Gritstone investment manager focused on commercialising life sciences and deep technology. She previously invested through Edinburgh’s Old College Capital and worked in university technology transfer.

Emma Jacobs is published as Executive Assistant with Future Planet Capital. She assists the executive chairman and brings more than30years of assistant experience, principally in finance. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Hassan Mahmudul is published as Investment Manager with Future Planet Capital. His work supports UKI2S; earlier experience includes founding two startups and venture scouting for Ada Ventures. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Huw Sparks is published as Investment Manager with Future Planet Capital. His work centres on the Midlands Engine Investment Fund; earlier experience includes boutique venture consulting and economics/politics studies at Birmingham. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Jessica Hill is published as Director of IR & Strategic Partnerships with Future Planet Capital. Her earlier work was in Gresham House’s housing business; she studied politics and leadership at Exeter. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Jim O’Neill chairs Northern Gritstone. His career includes leadership in Goldman Sachs research and asset management and public work on regional development and antimicrobial resistance.

Jordan Ong is published as Investment Associate with Future Planet Capital. He invests in the West Midlands through MEIF and co-investment programmes, following work at the Development Bank of Wales. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Julie Davies is published as Fund Accountant with Future Planet Capital. She is a chartered accountant and tax adviser whose Deloitte and EY experience focused on entrepreneurial companies. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Luize Silina is published as Investment Analyst with Future Planet Capital. She works in the regional investment team based in Birmingham. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Mark White is an investment director at Future Planet Capital and leads UKI2S fusion investing. His background includes UK investment banking and NESTA investment operations.

Norman Foster is published as Chair of Advisory Board with Future Planet Capital. He is an architect and design-practice leader and established the Norman Foster Foundation. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Oliver Sexton is published as Investment Director with Future Planet Capital. He is an experienced life-sciences and deep-technology investor with UKI2S investment-committee responsibilities, earlier buy-side analysis and strategy experience. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Peter Mitchell is published as Director, Data Science & Technology with Future Planet Capital. His research background includes statistical projects for the UK Cabinet Office and OECD, postgraduate study at Harvard and doctoral work at Oxford. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Rebecca Starkings is published as Compliance Officer, MLRO with Future Planet Capital. Her compliance career includes more than15years in financial-crime controls, integrity, due diligence and investment monitoring. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Rupert Lyle is published as Investment Director with Future Planet Capital. His investment and portfolio-management career spans more than30years, and he leads the West Midlands Co-Investment Fund. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Sakura Holloway was Start Codon partner and head of diligence in its2019–2020 period. Her current UKI2S biography describes former Start Codon healthcare deal sourcing, prior Manchester Innovation Factory and OneVentures roles, Benitec IP work, molecular-biology background and IP-law masters training. Current UKI2S/Future Planet roles are preserved separately; no exact historical departure date inferred.

Sam Martin is published as Portfolio Director with Future Planet Capital. He works with UKI2S portfolio companies on development and investment readiness. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Samantha Mills is published as Finance Associate with Future Planet Capital. Her finance work is supported by an AAT Level4 professional-accounting qualification. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Shruti Iyengar is published as Investment Director with Future Planet Capital. She supports UKI2S following venture investing at Sustainable Ventures, including responsibility for a36-company portfolio and development of impact measurement. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Surjit Kooner is published as Managing Director, Regional with Future Planet Capital. He is a chartered accountant with fundraising-advisory experience, MEIF fund-principal responsibilities and investment-committee membership. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Thomas Storey is published as Senior Associate with Future Planet Capital. His earlier work as a principal consultant at London Economics involved strategic analysis of the space sector. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Tony Stott is published as Investment Director with Future Planet Capital. He has extensive company-board experience and led a Midlands venture group from1998. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Sofilaro, currently branded Sofilaro Calen, is the Montpellier regional private-investment platform of Crédit Agricole Languedoc and Crédit Agricole Sud Méditerranée. It invests in growth and succession financing, innovative early-stage companies, renewable-energy infrastructure and private debt in six southern-French departments. Capital originates from the regional banks’ own balance sheets. Its historic investment company Sofilaro SAS (SIREN326224490), founded1983, is distinct from Sofilaro Gestion SAS (SIREN444598734), the2002 management company identified by the current website’s legal notice and statutory president of the investment vehicle. This broader platform profile preserves the actual named historical Cilcare buyer rather than substituting Crédit Agricole SA or assigning the old check to the2023 innovation vehicle. Current public management includes thirteen named people, with twelve published authentic portraits. Its six named investment vehicles are recorded with exact legal identities where verified; EUR350M platform assets under management, business-line AUM and published check limits are not completed fund-close amounts. A2017 Crédit Agricole Languedoc report explicitly confirms a EUR240,000 Sofilaro equity investment in Cilcare inJuly2017. Cilcare’s issuer also names Sofilaro in an earlierApril2024 financing and its December2024 latestEUR21M financing; individual2024 checks are undisclosed. The66-card own portfolio is a published selection, not claimed to represent all130-plus supported companies.

Khadija Ashfaq invests in science and technology businesses at Northern Gritstone, having previously backed North-East England companies at Northstar Ventures.

Harold Varmus, M.D. Harold Varmus was co-recipient of the 1989 Nobel Prize in Physiology or Medicine for studies of the genetic basis of cancer. In April 2015, he joined the Meyer Cancer Center of Weill Cornell Medicine as the Lewis Thomas University Professor of Medicine. He is also a senior associate member of the New York Genome Center, where he helps develop programs in cancer genomics. Previously, Varmus was the director of the National Cancer Institute for five years, the president of Memorial Sloan-Kettering Cancer Center for 10 years, and director of the National Institutes of Health for six years. A graduate of Amherst College and Harvard University in English literature and of Columbia University in medicine, he trained further at Columbia University Medical Center, the National Institutes of Health, and the University of California San Francisco (UCSF), before becoming a member of the UCSF basic science faculty for more than two decades. He is a member of the U.S. National Academies of Sciences and Medicine, and he is involved in several initiatives to promote science and health in developing countries. He also serves on advisory groups for several academic, governmental, philanthropic, and commercial institutions, including as co-chair of the Mayor’s LifeSci NYC and member of advisory boards for Chan-Zuckerberg Science and three biotechnology companies (Surrozen, Dragonfly, and PetraPharma). The author of about 400 scientific papers and five books, including a recent memoir, The Art and Politics of Science, Varmus was a co-chair of U.S. President Obama’s Council of Advisors on Science and Technology, a co-founder and chairman of the board of the Public Library of Science, and chair of the Scientific Board of the Gates Foundation Grand Challenges in Global Health.

Timothy M. Wright, M.D. Timothy M. Wright, MD, has been chief R&D officer at Regulus Therapeutics, a clinical stage biotech in San Diego, CA, since 2016. Over the past two decades, he has served in leadership positions from discovery research to late stage pharmaceutical development at Pfizer (2001-2004), Novartis (2004-2015), and the California Institutes for Biomedical Research (Calibr, 2015-2016). In these roles he has contributed to the development of numerous innovative medicines from concept to market. A native of Wilmington, Delaware, Wright attended the University of Delaware (BA, Biology) and received his medical and research training at the Johns Hopkins University School of Medicine (MD, Rheumatology, Immunology, Molecular Biology) and the Medical College of Virginia (Internal Medicine). In his early research career, he made advances in the understanding of the biochemistry and molecular biology of signal transduction. Wright held academic positions as a physician-scientist at Johns Hopkins and the University of Pittsburgh where his research was focused on the humoral, cellular, and molecular aspects of immune responses in autoimmune diseases. While at the University of Pittsburgh, he led the formation of the Pittsburgh Arthritis Institute, was chief of Rheumatology and Clinical Immunology and was the recipient of the Margaret J. Miller endowed Professorship for Arthritis Research, before moving to the pharmaceutical industry in 2001. Wright serves on the Board of Directors for Schrödinger, Inc. and ENYO Pharma, and as a scientific advisor to several academic and industry organizations.

Eric G. Pamer, M.D. Eric G. Pamer received his M.D. from Case Western Reserve University Medical School and completed clinical training in internal medicine and infectious diseases at University of California San Diego (UCSD) Medical Center. He was a postdoctoral fellow with Charles E. Davis at UCSD, with Maggie So at Scripps Research Institute, and with Michael Bevan at the University of Washington before he moved to Yale University. In 2000, he moved his laboratory to Memorial Sloan-Kettering Cancer Center (MSKCC) in New York, where he has been chief of infectious diseases and, more recently, head of the Division of Subspecialty Medicine. Pamer initially studied T cell responses to Listeria monocytogenes infection, demonstrating the efficiency of antigen presentation and the impact of antigen presentation and inflammation on T cell response magnitudes. Upon moving to MSKCC, he extended his research to inflammatory monocytes. In a series of studies, Pamer demonstrated that inflammatory monocytes differentiate into TNF and iNOS producing dendritic cells in response to L. monocytogenes. He demonstrated that CCR2 chemokine receptors drive monocyte emigration from bone marrow but not, as previously assumed, immigration into infected tissues. Pamer showed that bone marrow mesenchymal cells have hair-trigger responses to TLR-ligands and produce CCL2, driving monocytes into the bloodstream. He demonstrated that monocytes transport fungal spores and Mycobacterium tuberculosis from the lung to mediastinal lymph nodes and, during Mtb infection, transfer antigen to dendritic cells to prime CD4 T cells in lymph nodes. Because infections caused by highly antibiotic-resistant pathogens are a growing problem, Pamer has focused on Vancomycin-resistant Enterococcus (VRE) and Clostridium difficile infections and the defensive roles of mucosal immunity and the microbiota. A seminal study demonstrating that antibiotics reduce intestinal immune defenses and facilitate VRE infection was followed by discovery of commensal bacterial species that enhance antimicrobial defenses. Pamer focused on patients undergoing bone marrow transplantation and discovered dramatic microbiota diversity losses following transplantation. He also demonstrated that diversity loss is associated with increased mortality. Pamer’s work has led to the first randomized clinical trial to determine the feasibility and benefit of reintroducing a patient’s own intestinal microbiota following bone marrow transplantation.

Francine Ntoumi, Ph.D., HDR, PvDz, FRCPedin Francine Ntoumi serves as the chair and head of research of the Congolese Foundation for Medical Research. Born in Brazzaville in the Republic of the Congo, Ntoumi studied in France and got habilitation at University ParisVI (2002) and at University of Tübingen in Germany (2014). In Congo, Gabon, and Germany, she worked as a researcher, and she held positions in international organizations in the Netherlands and Tanzania from 2005 to 2010. Also during this time, she was the first African leader of the Multilateral Initiative on Malaria (MIM). During her career in malaria research, she trained many African scientists in various disciplines such as immunology and molecular epidemiology. Since 2009, Ntoumi has been highly involved in developing health research capacities in Central Africa through the regional network of excellence, the Central Africa Network on Tuberculosis, HIV/AIDS, Malaria (CANTAM). In the Republic of Congo in 2008, she created the Congolese Foundation for Medical Research (FCRM), which supports health research activities in the country. Her institution has established the first molecular biology lab at the University Marien Ngouabi, where she is senior lecturer. She is also highly engaged in promoting gender balance in science in the African region through an important program, “To make Science, a female ambition.” Ntoumi is member of several scientific and advisory committees and is involved in many international scientific networks in Africa, Europe, and the United States. She is a fellow of the African Academy of Science. In recognition of her efforts in developing research capacities in Africa, Ntoumi received the prestigious African Union Kwame Nkrumah Regional Scientific Award for women (2012), Germany’s Georg Forster Prize (2015), France’s Christophe Merieux Prize, and the Gold Medal for her contribution in science (research, training, advocacy, and transforming the environment) by the president of the Republic of Congo (2016).

Salim S. Abdool Karim, M.B.Ch.B, Dip.Data (computer science), M.S., M.Med, F.F.P.H.M., Ph.D., D.Sc.(hc) Salim S. Abdool Karim is a South African clinical infectious diseases epidemiologist who is widely recognized for his research contributions in HIV prevention and treatment. He is director of the Centre for the AIDS Program of Research in South Africa (CAPRISA) and CAPRISA professor of global health at Columbia University. He is also pro vice-chancellor (research) at the University of KwaZulu-Natal, South Africa, and adjunct professor of medicine at Cornell University in New York. He has served as the president of the South African Medical Research Council and is an associate member of the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard University. His clinical research on tuberculosis-HIV treatment has shaped international guidelines on the clinical management of co-infected patients. He was co-leader of the CAPRISA 004 tenofovir gel trial that provided proof-of-concept that antiretrovirals can prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. He is co-inventor on patents that have been used in several HIV vaccine candidates and in passive immunization strategies with broadly neutralizing antibodies. Abdool Karim is chair of the UNAIDS Scientific Expert Panel, WHO’s HIV Strategic and Technical Advisory Committee, and the WHO Tuberculosis-HIV Task Force. He serves on the boards of several journals, including the New England Journal of Medicine, Lancet Global Health, Lancet HIV, and mBio. He is a member of the Royal Society of South Africa, Academy of Science of South Africa, African Academy of Sciences, and the World Academy of Sciences (TWAS). He is a member of the U.S. National Academy of Medicine, the American Academy of Microbiology, and the Association of American Physicians. His awards include the TWAS Prize in Medical Sciences, the African Academy of Science’s Olusegun Obasanjo Prize for Scientific Discovery and Technological Innovation, the Science for Society Gold Medal Award from the Academy of Science in South Africa, the Platinum Medal Lifetime Achievement Award from the South African Medical Research Council, and Columbia University’s Allan Rosenfield Alumni Award for Excellence. The African Union awarded him the Kwame Nkrumah Continental Scientific Award, the most prestigious scientific award in Africa.

Shabir A. Madhi, M.B.B.C.H., FCPaeds, Ph.D. Shabir Madhi is professor of vaccinology at the University of the Witwatersrand in Johannesburg. He also holds the positions of director of the South African Medical Research Council Respiratory and Meningeal Pathogens Research Unit and he is research chair in vaccine preventable diseases at the Department of Science and Technology at the National Research Foundation. He is the immediate past director of the National Institute for Communicable Diseases (2011 to 2017), and he currently serves as the chair of the National Advisory Group on Immunization in South Africa. Author of more than 350 scientific publications, his research focus has been on epidemiology and clinical development of vaccines against pneumonia, diarrheal disease, and for maternal immunization. These studies have been pivotal to informing WHO and SAGE policy on the use of such vaccines in low-middle income countries. He has served as a temporary consultant/technical adviser to WHO in the field of pneumonia and vaccines. His scientific awards include European Society for Infectious Diseases Young Investigators Award (2006), as well as a number of national awards, including the 2009 National Science and Technology Forum: TW Kambule Award (2009), National Research Foundations President’s Award: Transformation of the Science Cohort (2010), Medical Research Council Lifetime Award platinum medal (2013), and the European and Developing Countries Clinical Trial Partnership Award for Scientific Leadership (2016). He is an elected member of the Academy of Science of South Africa (2012) and the Royal Society of South Africa (2016), and in 2017 he was elected as a fellow of the World Academy of Sciences.

Alan Bernstein, O.C., O.Ont., Ph.D,. FRSC Alan Bernstein is president of the Canadian Institute for Advanced Research (CIFAR), one of Canada’s major global research assets. From 2008 to 2011, Bernstein was the executive director of the Global HIV Vaccine Enterprise, an international alliance of researchers and funders charged with accelerating the search for an HIV vaccine. Previously, he served as the founding president of the Canadian Institutes of Health Research (2000 to 2007), Canada’s federal agency for the support of health research. In that capacity, he led the transformation of health research in Canada. After receiving his Ph.D. from the University of Toronto, and following postdoctoral work in London, Bernstein joined the Ontario Cancer Institute (1974 to 1985). In 1985, he joined the new Samuel Lunenfeld Research Institute in Toronto. He was named associate director in 1988, and he served as director of research from 1994 to 2000. Bernstein has written more than 225 scientific publications and has made extensive contributions to the study of stem cells, hematopoiesis, and cancer. He chairs or is a member of advisory and review boards in Canada, as well as in Italy, the U.K., and the United States. Bernstein has received numerous awards and honorary degrees for his contributions to science, including the 2008 Gairdner Wightman Award, induction into the Canadian Medical Hall of Fame, and the Henry G. Friesen International Prize in Health Research. He is a senior research fellow of Massey College and in 2002, he was appointed an officer of the Order of Canada.

John Bell, G.B.E., F.R.S., FMedSci (Chair of Committee) John Bell is the Regius Professor of Medicine at Oxford University. Bell went to Oxford as a Rhodes Scholar to train in medicine and undertook postgraduate training in London and at Stanford University. At Stanford, he developed research interests in the area of immunology and genetics, with a particular focus on characterizing the molecular events associated with susceptibility to autoimmune diseases. He returned to Oxford as a Wellcome Trust senior clinical fellow in 1987 and was elected to the Nuffield Professorship of Clinical Medicine in Oxford in 1992. In 1993, he founded the Wellcome Trust Centre for Human Genetics, one of the world’s leading centers for complex trait common disease genetics. In 2002, he became the Regius Professor of Medicine. Bell served as president of the Academy of Medical Sciences from 2006 to 2011. He was responsible for the working party that produced the academy’s highly influential “Strengthening Clinical Research” report that highlighted the need for the U.K. to focus some of its attention on developing expertise in translational research. In 2006, he was appointed by the chancellor of the exchequer to chair the Office for the Strategic Coordination of Health Research (OSCHR), and in December 2011, he was appointed one of two U.K. Life Sciences Champions by the prime minister. In collaboration with industry, academia, charity, and research organizations, Bell drafted the U.K. Life Sciences Industrial Strategy, which provides recommendations to the government on the long-term success of the life sciences sector. The report was published on August 30, 2017. In 2008, he was made a fellow of the Royal Society and a Knight Bachelor for his services to medical science. He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research, and the life science industry. Bell has been involved extensively in the development of research programs in genetics and genomics and in the development of a clinical research program across the U.K. He sits on a range of advisory panels for public and private sector bodies responsible for biomedical research in Canada, Denmark, France, Singapore, Sweden, and the U.K, and he is a founding director of three biotechnology start-up companies.

Margaret A. Hamburg, M.D. Margaret A. Hamburg, an internationally recognized leader in public health and medicine, is the foreign secretary for the U.S. National Academy of Medicine and the president of the American Association for the Advancement of Science (AAAS). She is the former commissioner of the U.S. Food and Drug Administration (FDA), having stepped down from that role in April 2015 after almost six years of service. As FDA commissioner, she was known for advancing regulatory science, streamlining and modernizing the FDA’s regulatory pathways, and globalization of the agency. Before joining the FDA, Hamburg was founding vice president and senior scientist at the Nuclear Threat Initiative, a foundation dedicated to reducing nuclear, chemical, and biological threats. Previous government positions include assistant secretary for planning and evaluation at the U.S. Department of Health and Human Services, health commissioner for New York City, and assistant director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health. Hamburg earned her B.A. from Harvard College and her M.D. from Harvard Medical School, and she completed her medical residency at Weill Cornell Medical Center. She is a fellow of the American Association for the Advancement of Science and the American College of Physicians, and is an elected member of the Council on Foreign Relations and the National Academy of Medicine. Hamburg sits on the boards of the Commonwealth Fund, the Simons Foundation, the Urban Institute, and the American Museum of Natural History. She is also a member of the Harvard University Global Advisory Council, the Global Health Scientific Advisory Committee for the Gates Foundation, the Harvard Medical School Board of Fellows, and the World Dementia Council. She is the recipient of multiple honorary degrees and numerous awards.

Tumani Corrah, M.D., Ph.D., F.R.C.P., P.P.W.A.C.P. Tumani Corrah is the unit director of the Medical Research Council Unit in the Republic of the Gambia. He joined the unit in 1982 as a junior clinician and progressed through the ranks as a research clinician and senior clinician, director of clinical services, and acting unit director. In 2004, he became the first African director of the U.K. Medical Research Council Unit in the Gambia. For more than two decades, Corrah has retained active research interests in tropical and infectious diseases, including tuberculosis, HIV, and malaria. His Ph.D. was groundbreaking, as he undertook one of the first trials of immunotherapy as an adjunct to the treatment of tuberculosis in Africa. He is a joint gold medal winner from the International Medical Informatics Association. He has served on the committees of many international organizations, including the African Aids Research Network (vice president), WHO Tuberculosis Task Force in Africa (member), Royal College of Physicians of London (international adviser), Royal Society of Tropical Medicine and Hygiene (international adviser), Visiting Committee of the London School of Hygiene and Tropical Medicine (member), and Partnership Board of the EDCTP (member). Corrah served as president of the West African College of Physicians and is currently the director of the college’s international office. An expert on research governance, he is a long-standing member of the Gambia government/MRC Ethics Committee, for which he served four years as chairman. He has strong links with governmental and nongovernmental organizations in Africa and throughout the world. An expert in capacity building, Corrah has been successful in establishing a number of productive, mutually beneficial North-South collaborations.

Yvonne Greenstreet, M.B.Ch.B, M.B.A. Yvonne Greenstreet has over 25 years of global experience in the healthcare and pharmaceutical industries, spanning drug development, general management, and corporate strategy. She has led product development and commercialization teams in a wide range of therapy areas of both small molecules and biologics and over the course of her career has brought numerous new medicines to market. Greenstreet is chief operating officer at Alnylam Pharmaceuticals. She was the founder and managing director of Highgate LLC, working with life sciences companies to help develop strategies that transform businesses, bring medicines to market, and maximize shareholder value. Previously, Greenstreet was senior vice president and head of Medicines Development at Pfizer from 2011-2013 and a member of the executive team with accountability for the $16bn Specialty Business. Greenstreet was at GlaxoSmithKline (GSK) from 1992- 2010, most recently as senior vice president and chief of strategy for Research and Development, and as a member of the product management board. She previously served in various positions of increasing responsibility at GSK, including senior vice president for Medicines Development, where she led the creation of a global unit with the responsibility for the development and commercialization of new products across a wide range of therapeutic areas. Greenstreet holds a bachelor of Medicine, bachelor of Surgery from the University of Leeds, United Kingdom and MBA from INSEAD, France.

Zulfiqar A. Bhutta, M.B.B.S., D.C.H., F.R.C.P., F.R.C.P.C.H., F.C.P.S., F.A.A.P., Ph.D. Zulfiqar A. Bhutta is the Robert Harding Inaugural Chair in Global Child Health at Toronto’s Hospital for Sick Children, co-director of the SickKids Centre for Global Child Health, and the founding director of the Centre of Excellence in Women and Child Health at the Aga Khan University. He also holds adjunct professorships at several leading universities, including the School of Public Health at Johns Hopkins University, Tufts University, Boston University School of Public Health, University of Alberta, and the London School of Hygiene and Tropical Medicine. He is Distinguished National Professor of the Government of Pakistan and was the founding chair of Pakistan’s National Research Ethics Committee from 2003 to 2014. Bhutta was a member of the Independent Expert Review Group (iERG) appointed by the UN Secretary General for monitoring global progress in maternal and child health MDGs (2011 to 2015). He represented the global academic and research organizations on the Global Alliance for Vaccines and Immunizations (Gavi) board, and he also serves on Gavi’s Evaluation Advisory Committee. Bhutta was the co-chair of the Global Countdown for 2015 and 2030 Initiatives (2006 to 2017). He is the co-chair of the Maternal and Child Health oversight committee of WHO’s Eastern Mediterranean Region and the chairman of the Coalition of Centres in Global Child Health, whose secretariat is based at Toronto’s Hospital for Sick Children. He is a technical member of the high-level UN Health and Human Rights committee and an executive committee member of Partnership for Maternal, Newborn, and Child Health (PMNCH). Bhutta was educated at the University of Peshawar and obtained his Ph.D. from the Karolinska Institute, Sweden. He is a fellow of the Royal College of Physicians (Edinburgh and London), the Royal College of Paediatrics and Child Health (London), American Academy of Pediatrics, and the Pakistan Academy of Sciences. He heads a large research team in Pakistan working on issues of maternal, newborn, and child survival and nutrition globally and regionally. Bhutta has served as a member of WHO’s Global Advisory Committee for Health Research, the board of the Child and Health and Nutrition Initiative of the Global Forum for Health Research, and the steering committees of the International Zinc and Vitamin A Nutrition Consultative Groups. He was a founding board member of the PMNCH and a board member of the International Center for Diarrheal Diseases Research (2011 to 2017). Bhutta was a member of the WHO Strategic Advisory Committee for Vaccines (SAGE) from 2010 to 2015 and the Advisory Committee for Health Research of the WHO EMRO. He is the former president of the Commonwealth Association of Paediatric Gastroenterology and Nutrition (CAPGAN) and the Federation of Asia-Oceania Perinatal Societies (FAOPS). He is the current president of the International Pediatric Association (2016 to 2019), and he serves as a leading voice for health professionals supporting integrated maternal, newborn, and child health globally. Bhutta is on several international editorial advisory boards, including the Lancet, BMJ, PLoS Medicine, PLoS ONE, BMC Public Health, and the Cochrane CDPLG and ARI groups. He has published eight books, 88 book chapters, and more than 800 indexed publications to date, including more than 150 in the world’s leading journal, Lancet. He is one of the most highly cited academics in global health (H index 117, i10 index 537, with more than 72,000 citations) and was ranked among the top 1 percent of highly cited researchers globally by the Web of Science in 2017. He has been a leading member of major Lancet series on child survival (2003), newborn survival (2005 and 2014), undernutrition (2008 and 2013), primary care (2008), stillbirths (2011 and 2016), and Pakistan (2013). He has also been a leading member of the recent series on childhood diarrhea and pneumonia (2013) and early child development (2016), and Lancet commissions on education for health professionals for the 21st century (2010), women and health (2015), indigenous health (2016), and adolescent health (2016). He has won several awards, including the Tamgha-i-Imtiaz (Medal of Excellence) by the president of Pakistan for contributions to education and research (2000), the president of Pakistan’s gold medal for contributions to child health in Pakistan (2004), and the Outstanding Pediatrician of Asia award by the Asia Pacific Pediatric Association (2006). He is the first dual recipient of the Aga Khan University Distinguished Faculty Award for Research (2005) and Award of Distinction (2012). Bhutta was awarded the inaugural Programme for Global Pediatric Research Award for Outstanding Contributions to Global Child Health (2009) and the Kenneth Warren Prize for the best systematic review of community-based interventions by the Cochrane collaboration (2011). Bhutta was awarded the Global Advocacy Prize by the Royal College of Paediatrics and Child Health (2012), the American Academy of Pediatrics’ Sam Fomon Award for lifetime contributions to nutrition research (2014), the WHO Ihsan Dogramaci Family Health Award (2014), the inaugural TUBA Academy of Sciences Award for global contributions to health and life sciences (2015), University of Toledo Medical Missions Hall of Fame Award (2016), and the Geneva Forum for Health Award for contributions to maternal and child health globally (2016). In August 2016, Bhutta was recognized with the president of Pakistan Pride of Performance Award for contributions to education and health. In November 2016, the World Academy of Sciences (Trieste) awarded him the TWAS Prize in Medical Sciences, and in 2017 the Pakistan Council for Science and Technology rated Bhutta as the highest ranking scientist from Pakistan across all disciplines. In November 2017, he was recognized by the Senate of Canada with its Canada 150 Medal for contributions to global child health. Bhutta’s research interests include newborn and child survival, maternal and child undernutrition, and micronutrient deficiencies. He leads large research groups based in Karachi, Nairobi, and Toronto, with a special interest in research synthesis, expanding evidence-based interventions in community settings, and implementation research in health systems research. His work on community health staff and outreach services has influenced integrated maternal and newborn outreach programs for marginalized populations globally. His group’s work with WHO and PMNCH in developing consensus-based essential interventions for women, children, and adolescents is the dominant set of agreed interventions guiding global policy.

Dr Ann Taylor is an experienced clinical investigator and pharmaceutical executive with 20 years experience in the pharmaceutical industry, serving in multiple leadership roles at multiple companies. She was Chief Medical Officer at AstraZeneca from 2019-2021 where she was responsible for employee and patient safety during the COVID epidemic, AstraZeneca’s Patient Safety, Quality Assurance, and Regulatory Policy organizations, and the overall Benefit Risk assessment of our medicines. Prior to joining AstraZeneca in 2018, Ann was Vice President and Global Head of the Program Office for the Novartis Institutes for BioMedical Research (NIBR), responsible for portfolio management, strategy, and project management. She also previously served as Global Head, Translational Medicine at NIBR, after having positions of increasing responsibility in early clinical development at Pfizer Global Research and Development. Ann received her M.D. from Harvard Medical School, after receiving her B.A. in Biology magna cum laude from the University of California, San Diego. She completed her internship and residency in Internal Medicine, and her fellowship in Endocrinology and Metabolism at Massachusetts General Hospital, where she served on the faculty as a clinician, investigator, teacher, and administrator for 11 years. She is passionate about bringing the patient voice to clinical trials and has a particular interest in health equity and women’s health. Ann currently serves on the Boards of Comanche Biopharma and UnLearn AI, as well as two non-profits, the TBAlliance and the New England Advisory Board of the Trust for Public. She also serves as Co-Chair of the National Academies of Science, Engineering and Medicine Forum on Drug Discovery, Development, and Translation and is a member of the Alumni Council at Harvard Medical School.

Mumbai, India Sandeep is a Senior Advisor and Investment Committee Member at Avaana Capital, India’s leading early-stage climate action and sustainability fund. He is a Board Member of Titan Company Limited, chairs the Risk Management Committee and is a member of the Audit and Nomination & Remuneration Committees. He is on the board of HT Media, India’s largest listed media company. Sandeep is also an independent investment committee member of the Mars Equity Dragon Fund and a Governing Council Member of Marico Innovation Foundation. He is a Board Member and leads healthcare philanthropy at ACT Grants, a platform to accelerate the deployment of innovative digital solutions in the public domain in India. The focus in public health is in the areas of Tuberculosis, Oncology, Mental Health and Rural Access. Sandeep has 35 years of experience across venture capital, entrepreneurship, and management consulting. He co-founded Nexus Venture Partners in 2006 and grew it to $1.5B of AUM, was a General Partner till 2021, and is now a Senior Advisor. Prior to Nexus, he co-founded eVentures India in 1999. eVentures was one of the earliest Indian VCs and backed market leaders like MakeMyTrip, NTT NetMagic Solutions and Firstsource/CustomerAsset. Sandeep received an MBA (with Distinction) from The Wharton School of the University of Pennsylvania with a dual Major in Finance and Marketing, and a BS in Electrical Engineering from Stanford University, where he was elected to Phi Beta Kappa and Tau Beta Pi. He is the past President of the Stanford Alumni Association of India and a Stanford Associate.

London Nimit Shah joined Vivo Energy as CFO in May 2024. Before joining Vivo Energy he was a partner in the investment team and Head of Debt Capital Markets at Africa-focused private equity firm, Helios Investment Partners. At Helios, he has led deals in more than 30 African markets, worth around $2bn of value. These include GBFoods Africa, Interswitch, Continental Outdoor, and OVH Energy. He was also involved in the original deal when Vitol and Helios acquired Shell’s downstream Africa business to create Vivo Energy in 2011. Nimit holds an MBA from Wharton School of Business, and an MA in Economics and Management from Oxford University.

Keith Matthews manages the foundation’s legal team and oversees a broad range of legal, transactional, policy, operational, and programmatic matters that affect the foundation and its subsidiaries and their ability to achieve their respective missions. Keith serves on the board of Bill & Melinda Gates Agricultural Innovations, a foundation subsidiary that focuses on developing agricultural technologies and innovations. He also serves on the investment committees of the foundation’s Strategic Investment Fund and the Innovative Financial Instruments team. Before Keith joined the foundation, his legal work focused on corporate transactions and governance matters. He counseled private equity investors on a wide range of transactions, including growth equity and venture capital investments and mergers and acquisitions. Over the course of his career, he was seconded to the African Development Bank in Tunisia, where he represented the bank in public and private financings in sub-Saharan Africa, and he worked in Singapore as a lawyer focused on project financings. Keith has also worked as a management consultant and a commercial banker based in New York. Keith has a B.S. in finance from the Wharton School at the University of Pennsylvania and a J.D. from the University of Michigan.

Tracia Luh leads a team that provides financial and strategic planning and analytical support across the foundation’s work in global health. She also leads the foundation’s Business Development & Licensing team, which structures investments with private-sector business partners to advance the foundation’s mission and charitable purpose. Tracia joined the foundation in 2016 as chief financial officer of the U.S. Program, which largely focuses on education. Earlier, she served as CFO of Andela, a talent accelerator funded by the Chan Zuckerberg Initiative and other investors that trains software developers in Africa and places them with leading global companies. She also served as CFO and senior vice president of corporate development at Newsweek, a division of Graham Holdings / Washington Post, where she was hired to lead a financial review of strategic alternatives that culminated in the sale of the division. From 2000 to 2009, Tracia held senior financial positions at ESPN/Disney, assessing operating performance and evaluating strategic transactions and investments. She began her career in the Global Fixed Income departments at Merrill Lynch and Chase / J.P. Morgan, analyzing companies and publishing investment recommendations. Tracia has a bachelor's degree from the Wharton School at the University of Pennsylvania and an MBA from the Kellogg School of Management at Northwestern University. She serves on the boards of the YMCA of Greater Seattle, which manages 13 Seattle-area branches, and Lincoln Center Education, which provides arts education programs to underserved schools and communities.

Sundar Kodiyalam is a seasoned investor and biotechnology executive with extensive experience across venture capital, biopharmaceutical strategy, and corporate development. He is a co-founder and served for more than a decade as Managing Director of Vatera Healthcare Partners, a family office-based venture capital firm, focused on investments in innovative life sciences and healthcare companies. Mr. Kodiyalam has held senior leadership roles in the biopharmaceutical industry, including Senior Vice President of Commercial Development and New Business Ventures at Kos Pharmaceuticals, where he played a central role in shaping the company’s late-stage pipeline, strategic partnerships, and growth strategy prior to its acquisition by Abbott Laboratories. His earlier career includes commercial and business development leadership positions at Ortec International, Schering-Plough Corporation, and Novartis Pharmaceuticals, with responsibilities spanning global marketing, new product management, licensing, and strategic alliances. In addition to his operating and investment experience, Mr. Kodiyalam has served and continues to serve on the boards of numerous private and public biotechnology and healthcare companies. Mr. Kodiyalam holds a Bachelor of Pharmacy from Madras University in India and a Master of Science in Pharmaceutical Administration from The Ohio State University.

Patrick James Heron, published by Frazier Life Sciences as Patrick Heron, is a managing partner at Frazier Life Sciences and a member of the Gates Foundation Strategic Investment Fund Investment Committee. The foundation publishes his authentic Frazier portrait and current committee affiliation.

Matt is a corporate and transactional attorney with over 25 years of experience negotiating and documenting complex investments. During his 11 years at the foundation he has been the lead transaction counsel on more than 50 completed program-related investments, mission-related investments and other innovative financing transactions involving entities in over a dozen different countries. Prior to joining the foundation, he spent 15 years at K&L Gates LLP where he was a partner in the corporate/securities group. At K&L Gates he represented public and private companies in the full range of corporate and securities law matters, including corporate and limited liability company formations, joint ventures, mergers and acquisitions, public and private securities offerings, compliance with state and federal securities laws, stock exchange listing and corporate governance. He also represented clients in negotiating and drafting prime brokerage documentation, ISDA agreements and futures documentation. He is a graduate of Stanford University and the UCLA School of Law.

Jill manages the coordination of all strategic investments and contracts including data management and analysis. She acts as a primary point of contact for internal and external stakeholders ensuring deliverables and deadlines of portfolio investments are met. Prior to joining the foundation, Jill was an Administrative Assistant at Educational Services of America. Jill earned her B.A. and M.B.A. from the University of North Alabama.

Ken is a corporate and securities attorney who provides strategic advice and practical solutions in connection with the foundation’s program-related investments and other complex transactions, as well as advising on securities compliance matters and general corporate governance.

Logan Morwick Miller joined the Gates Foundation in 2023 and serves as an Associate of the Strategic Investment Fund (SIF). Since joining, Logan has evaluated and structured investments in the biotech, agriculture technology and education technology sectors, as well as volume guarantees supporting new HIV PrEP products. She is the Foundation’s Board Observer for Carnegie Learning and Vedanta Biosciences. Prior to joining the Foundation, Logan worked in the Private Capital division of the Ontario Teachers’ Pension Plan, where she evaluated, executed, and monitored investments in the Diversified Industrials and Business Services sectors. Logan also worked as an Investment Banking Analyst at TD Securities in Toronto. Logan received her BA in Honors Business Administration from the Ivey Business School, at Western University.

Susan is a corporate attorney who advises on the foundation’s program-related investments, innovative finance investments and other complex transactions across the foundation. Prior to joining the foundation, Susan was counsel at the United States Development Finance Corporation (DFC) where she specialized in project finance investments in the renewable energy, healthcare, infrastructure and microfinance sectors in Latin America, Africa and Southeast Asia. Susan began her career as a corporate attorney at Cleary Gottlieb Steen & Hamilton LLP in New York City. She graduated magna cum laude from Columbia College, Columbia University and with honors from Columbia Law School.

Antonio Garcia Maldonado is a Partner at SIF. He works on international investments with a focus on biotech in Europe and Israel, and tech-enabled service/product delivery in South Asia and Sub-Saharan Africa. Prior to joining the foundation, Antonio worked in the investment banking division at JPMorgan. There, he worked on structuring and executing M&A, equity and debt transactions across the Technology and Healthcare industries. Antonio obtained his Bachelors of Laws and Bachelors in Business Administration from ICADE – Universidad Pontificia de Comillas (Madrid, Spain); and his Graduate Diploma in Law and in Human Rights Law from the University of Law and the London School of Economics and Political Science respectively.

Elisabeth joined the Gates Foundation in March 2026 and serves as an Associate of the Strategic Investment Fund (SIF), where she works as a generalist across the Fund’s investment areas. Prior to joining the Foundation, Elisabeth was an Investment Banking Analyst at Morgan Stanley within the Industrials Group in New York City, where she executed buyside, sellside, and IPO transactions across the data center, automotive, and industrial technology sub-sectors. Elisabeth holds a Bachelor’s degree from Columbia University, where she double-majored in Economics and Political Science.

Kristin provides operational support to the Strategic Investment Team. She received a B.S. in hospitality and tourism management from Virginia Tech University focusing on event management. Starting as a contractor for the Gates Foundation five years ago, Kristin joined full-time soon after and has been with the SIF team for three years. Kristin focuses on processing Programmatic Related Investments for the SIF team and the Accelerator team, shepherding new investments from start to finish. She works closely with internal and external partners to ensure all compliance standards are met and that new partners are introduced to foundation practices.

Jessica joined the Gates Foundation in July 2025 as Senior Coordinator providing operational support to the Strategic Investment team. Prior to joining the Gates Foundation, Jessica built a career spanning more than 20 years in operations, human resources, executive support, and business administration within the biotechnology, pharmaceutical, and investment sectors. She spent over two decades with Accelerator Corporation, where she served in senior operational leadership roles supporting venture creation, portfolio company development, investor relations, and executive operations. During her tenure, she worked closely with leadership teams and helped establish and scale multiple early-stage life sciences companies. Before joining Accelerator, Jessica worked at Prolinx, Inc., a venture-backed biotechnology company focused on technologies supporting drug discovery. There, she managed a broad range of operational and marketing functions supporting the company’s growth and commercialization efforts. Jessica received a Master of Business Administration from Seattle University and a Bachelor of Arts in History from the University of Washington.

Rutendo joined the Gates Foundation in 2026 and serves as Investment Officer for the Strategic Market Tools initiative within the Strategic Investment Fund (SIF). She partners with program strategy teams to structure, negotiate, and execute complex transactions with private sector entities, multilaterals, and governments, using guarantees and other structured/innovative finance tools to lower the cost of critical health commodities and expand access in the foundation’s priority geographies. Prior to joining the foundation, Rutendo worked in Innovative Finance at the United Nations. Earlier, she was a Vice President in Lazard’s Special Opportunities team, reporting directly to the CEO, where she focused on strategic and sovereign advisory and M&A. She began her career at Bridgewater Associates, where she served as an Investment Associate and went on to be a team lead on the firm’s Onshore China and Portfolio Strategy work. Rutendo holds a BA from the University of Pennsylvania. She also holds a Master of Public Policy and an MBA from the University of Oxford, where she studied as a Rhodes Scholar. A native of Zimbabwe, Rutendo brings strong personal conviction to her work on health and economic opportunity across the developing world.

Zainab Bakrin is an Associate at the Gates Foundation’s Strategic Investment Fund, focused on the Biotech Accelerator program. Prior to joining the Gates Foundation in 2024, Zainab was a member of the investment team at Casdin Capital, where she focused on life science tools, diagnostics, healthcare IT, and industrial applications of biotechnology. Zainab started her career in investment banking at Goldman Sachs and holds a B.A. in Neuroscience from Dartmouth College. Zainab has lived in Lagos, Nigeria; Johannesburg, South Africa; New York City and is currently based in Seattle. She enjoys playing soccer, cycling, and supporting women’s sports in her spare time.

While she maintains a diverse portfolio, Julie spends the majority of her time focused on healthcare delivery, which comprises debt, equity, and volume guarantee investments that improve primary healthcare, maternal and child health, and infectious disease. Recognizing that there will never be enough trained medical providers, she focuses on the role that technology-enabled diagnostics, devices, and software can enable doctors, midwives, and community health workers to provide higher-quality care in low- and middle-income countries. Prior to her investment career on the SIF team, Julie was Chief of Staff to the foundation’s CFO. Before joining the foundation in 2008, Julie held finance roles at a publicly traded company and with a microfinance organization in Nicaragua. She began her career in public accounting at KPMG. Julie holds a B.B.A. in Finance and Accounting from Gonzaga University.

Vanessa Bhark is a Principal at the Gates Foundation’s $2.5 billion Strategic Investment Fund (SIF), the foundation’s venture capital, debt, and guarantee fund. Prior to joining the Gates Foundation in 2021, Vanessa was a member of the investment team at Frazier Healthcare Partners, focused on biopharmaceuticals. Vanessa has also held positions in corporate and business development at Gilead and J&J, leading the diligence and structuring of partnerships, licenses and acquisitions for novel pharmaceutical technologies. Vanessa started her career in biotech equity research at Morgan Stanley. Vanessa has an M.B.A. from the Kellogg School of Management and a Bachelor of Science in Chemical Engineering from MIT.

Ryan Kreitzer joined the Strategic Investment Fund in 2014. Based in Seattle, Ryan invests across fintech, healthtech, agritech & climate, focusing on innovative companies that develop new solutions to long-standing challenges that impact patients, farmers and consumers globally. He also leads SIF’s investing practice in Sub-Saharan Africa, where he invests in businesses that deliver innovations to those that need them most. He currently serves as the Gates Foundation’s board observer on a number of companies, including Pula Advisors and Enko. Prior to joining the foundation, Ryan worked in investment banking at Evercore. There, he advised on mergers and acquisitions, spin-offs, and strategic transactions involving clients across a variety of industries. Ryan graduated from New York University’s Stern School of Business with a B.S. in Finance and Economics.

David Rossow joined the foundation in 2010 as part of a $400 million pilot to establish the Strategic Investment Fund. He currently heads the fund’s international work with a focus on biotech in Europe, and tech-enabled service & product delivery in South Asia and Sub-Saharan Africa. Prior to joining the foundation in 2010, David worked on deal teams in private equity and investment banking, where he was responsible for executing leveraged buyout, equity, debt, restructuring, and merger & acquisition transactions across a variety of industries. David holds a B.A. in Economics from St. Olaf College.

Natalie Revelle leads the Volume Guarantee initiative and structured financing investments within the SIF team. Working with pharmaceutical companies, sovereign and private foundation partners, donors, and implementing partners, Natalie has structured a portfolio of investments across global health commodities including vaccines, family planning, and HIV products that is expected to generate over $1 billion of procurement savings. Natalie also serves as senior financial advisor to the CFO for complex transactions for achieving impact and as a subject matter expert on how programs can bring about impact through financial tools. Prior to joining the foundation, Natalie held a number of strategy and financial advisory roles. Most recently, Natalie worked at McKinsey & Company where she served high tech clients on strategy development, procurement, and pricing topics. Natalie is a graduate of Harvard Business School and Princeton University with a Bachelor of Arts in Economics.

Thong Q. Le joined the Gates Foundation in December 2024 and serves as Investment Director and Managing Partner of the Strategic Investment Fund (SIF), the Foundation’s impact investment arm. In this role, he leads the use of equity, debt, guarantees, and other investment tools to advance the Foundation’s philanthropic goals. Thong brings more than 25 years of investment and leadership experience across the life sciences industry, with a track record of building companies, making impact-oriented investments, and developing investment strategies designed to improve lives. Prior to joining the Gates Foundation, Thong served as Senior Managing Director and CEO of Accelerator Life Science Partners (ALSP), a venture capital firm focused on creating and developing next-generation life sciences companies. After joining ALSP in 2013, he helped shape the firm’s strategy and led its expansion beyond the Pacific Northwest. He also served as a director and founding President & CEO of more than a dozen ALSP portfolio companies, including Petra Pharma (acquired by a global pharmaceutical company in 2020); Rodeo Therapeutics (acquired by Amgen Inc. for up to $721 million in 2021); and Lodo Therapeutics (acquired by Zymergen in 2021, now Ginko Bioworks). Before joining ALSP, Thong spent nearly 15 years as Managing Director of WRF Capital, the venture investment arm of the Washington Research Foundation, where he invested in and supported the growth of early-stage life sciences and technology companies. Thong received his A.B. in Government from Harvard University and undertook postgraduate studies in business at Templeton College, Oxford University.

As a trustee from 2006 – 2021, Warren Buffett worked along with Bill Gates and Melinda French Gates to help shape our vision and develop strategies to address some of the world's most challenging inequities. Buffett is a U.S. businessman and philanthropist. As chairman and chief executive officer of Berkshire Hathaway Inc., he has invested in a broad range of companies, from See's Candies to Geico Insurance to Fruit of the Loom. Through 2022, Warren’s contributions to the Gates Foundation total $36 billion valued at the time of receipt. Warren attended the Wharton School at the University of Pennsylvania and received his bachelor's degree from the University of Nebraska. In 1951, he earned a master's degree in economics from Columbia University. Warren and his late wife, Susan Thompson Buffett, raised three children: Susie, Howard, and Peter. Now married to Astrid Menks Buffett, Warren lives and works in his hometown of Omaha, Nebraska. The impact of [Warren’s] prodigious generosity is hard to quantify. Even harder to quantify is how his values have permeated the foundation’s culture. - Mark Suzman Chief Executive Officer, Gates Foundation

William H. Gates Sr. d. 2020) guided the vision and strategic direction of the foundation and served as an advocate for the foundation’s key issues. He first answered his son's request for help in using his resources to improve reproductive and child health in the developing world by directing the William H. Gates Foundation, which was established in 1994. It merged with the Gates Learning Foundation to create the Gates Foundation in 2000. Bill Sr. earned his bachelor's and law degrees from the University of Washington, following three years of U.S. Army service in World War II. A founding partner at Preston Gates & Ellis, Bill Sr. served as president of both the Seattle/King County Bar Association and the Washington State Bar Association. He has served as trustee, officer, and volunteer for more than two dozen Northwest organizations, including the Greater Seattle Chamber of Commerce and King County United Way. In 1995, he founded the Technology Alliance, a cooperative regional effort to expand technology-based employment in Washington. Bill Sr. was also a strong advocate for education for many years, chairing the Seattle Public School Levy Campaign in 1971 and serving as a member of the University of Washington's Board of Regents from 1997-2012. Bill Sr. and his first wife, Mary Maxwell Gates (d. 1994), raised three children Kristianne, Bill , and Libby. For many years, he continued his lifelong commitment to many civic programs, cultural organizations, and business initiatives. He passed away on September 14, 2020 and is survived by his second wife, Mimi Gardner Gates, his three children, and eight grandchildren.

Melinda French Gates is a philanthropist, businesswoman, and global advocate for women and girls. She founded and co-chaired the Gates Foundation, where, for more than two decades, she set the direction and priorities of the world’s largest philanthropy. Melinda left the Gates Foundation in June 2024. For over 25 years, Melinda has led efforts to unlock a healthier, more prosperous, more equal future. Today, she heads Pivotal, an organization she formed in 2015 that works to accelerate the pace of progress and advance women’s power and influence in the U.S. and around the world. Pivotal drives impact using high-impact investments, philanthropy, partnerships, and advocacy. Melinda has seen firsthand how empowered women and girls transform families, communities, and countries. In her bestselling book, The Moment of Lift, she introduces readers to women whose stories have inspired her and writes about her own journey to becoming an advocate. Through her imprint, Moment of Lift Books, she amplifies other voices by publishing original nonfiction from visionaries working to unlock a more equal world for women and girls. The second of four children, Melinda grew up in Dallas, Texas. She attended Duke University, where she received a bachelor’s degree in computer science and economics and an MBA. Melinda spent the first decade of her career developing multimedia products at Microsoft before leaving the company to focus on her family and philanthropic work. Melinda has three children—Jenn, Rory, and Phoebe—and lives in Seattle, Washington.

Tom Tierney co-founded The Bridgespan Group , an independent global nonprofit focused on helping philanthropists and nonprofit leaders achieve breakthrough results. Over two decades, his leadership has nurtured Bridgespan’s growth and innovation. He is a recognized thought leader in philanthropy, having collaborated with a wide range of grantmakers on issues ranging from strategy to organization. His aspiration is to help increase the flow and effectiveness of philanthropy in ways that reduce inequities. He has served on the foundation’s board of trustees since January 2022. Prior to launching Bridgespan, Tom served as Bain & Company’s worldwide managing partner, where he successfully led the firm through an aggressive phase of innovation and global expansion. A co-author of two highly respected books, Aligning the Stars , and Give Smart: Philanthropy That Gets Results , he has also advised, served on and/or led numerous boards. Most recently he served as chair of The Nature Conservancy , eBay , and Stanford’s Hoover Institution . He is the longstanding chair of the Harvard Business School’s Social Enterprise Initiative and he co-chairs Bridgespan’s board. Tom was the fifth person to hold the class of 1951 Chair for the Study of Leadership at West Point. In 2016, he was the recipient of HBS’s Alumni Achievement Award. Born in San Francisco, California, Tom received his BA in Economics with highest distinction from the University of California at Davis. Upon graduation, he worked as a field engineer for Bechtel in Algeria. In 1980 he earned an MBA with distinction from the Harvard Business School.

* Minouche is currently on leave of absence from her foundation role. Minouche Shafik is an economist, policymaker, and higher education leader who has spent over three decades in leadership roles across a range of prominent international, national, and academic institutions. Effective September 2025, Minouche has taken a leave of absence from the foundation board, following her appointment as Chief Economic Advisor to U.K. Prime Minister Sir Keir Starmer. Previously, she was president of Columbia University and of the London School of Economics and Political Science (LSE), where she drove academic excellence, improved student experience, and raised substantial philanthropic support. Before that, Minouche served as deputy governor of the Bank of England, where she led work on fighting misconduct in financial markets and managed a balance sheet of around US$600 billion. She served on all of the bank’s policy committees which included the Monetary Policy Committee, the Financial Policy Committee, and the Board of the Prudential Regulatory Authority. Before joining the Bank of England, she was deputy managing director of the International Monetary Fund (IMF), where she navigated the turbulence surrounding the European debt crisis and the Arab Spring and modernized the IMF’s approach to building economic policy capacity in member countries. She was also responsible for the IMF’s US$1 billion administrative budget and US$10 billion pension fund. Before joining the IMF, Minouche served as permanent secretary of the UK government’s Department for International Development (DFID). Her tenure there coincided with DFID being ranked the best-performing department in government, and she helped secure the UK’s commitment to giving 0.7% of GDP to fight poverty in the world’s poorest countries. At age 36, Minouche became the youngest-ever vice president of the World Bank, where she worked on the institution’s first-ever report on the environment, led work on infrastructure and private-sector investment, and advised governments in post-communist Eastern Europe. She led policy work and published books on the prospects for economic progress in the Middle East during the Oslo peace process. Minouche received a B.A. from the University of Massachusetts Amherst, an M.Sc. from LSE, and a D.Phil. from St Antony’s College at Oxford University. She holds a life peerage and is a crossbench member of the House of Lords, received a damehood for services to the global economy, an honorary fellowship of the British Academy and of St Antony’s College at Oxford, and has six honorary doctorates. Her most recent book, What We Owe Each Other: A New Social Contract for a Better Society , has been translated into 12 languages. She has served as deputy chair and a trustee of the British Museum, the Council of the Institute for Fiscal Studies, and a governor of the National Institute of Economic and Social Research. She has been a member of the board of the Gates Foundation since 2022.

Strive T. Masiyiwa is a Zimbabwean based in London and an international business leader. He has served on the foundation’s board of trustees since January 2022. Masiyiwa is the Founder and Executive Chairman of South Africa-based Econet Group and Cassava Technologies and is one of the pioneers of the mobile telecoms industry on the African continent. Masiyiwa has also been involved in the development of Africa’s independent media. In May 2020, Masiyiwa was appointed to serve as an African Union Special Envoy to help coordinate Africa’s private sector efforts to procure medical supplies and fight the spread of COVID-19. As Special Envoy he also heads up the Africa Vaccine Acquisition Task Team. He led a similar private sector initiative to fight Ebola in West Africa in 2014-2015. Masiyiwa is a member of the Giving Pledge. In 1996, he and his wife, Tsitsi, cofounded what is now known as the Higherlife Foundation which has supported the education of over 250,000 orphaned, vulnerable, and gifted children across Africa, as well as health, disaster relief and preparedness, and rural transformation programs. Masiyiwa received a bachelor of engineering degree from the University of Cardiff.

Dr. Helene D. Gayle served as president of Spelman College, the No. 1 historically Black college or university in the country. A global leader in the education of women of African descent, Spelman College is dedicated to academic excellence in the liberal arts and sciences and the intellectual, creative, ethical, and leadership development of its students. Previously, Helene was president and CEO of The Chicago Community Trust, one of the nation’s oldest and largest community foundations. Under her leadership, the Trust adopted a new strategic focus on closing the racial and ethnic wealth gap in the Chicago region. An internationally recognized expert on health and humanitarian issues, as well as global and domestic economic development, Helene spent nearly a decade as president and CEO of the international humanitarian organization CARE. Prior to that, Helene served as the director of the HIV, TB, and Reproductive Health program at the Gates Foundation. She began her career at the Centers for Disease Control and Prevention, where she spent 20 years focusing primarily on HIV/AIDS prevention and global health. Helene serves on several public company and nonprofit boards, including the Coca-Cola Company, Organon, Palo Alto Networks, Brookings Institution, Center for Strategic and International Studies, New America, and ONE. She is a member of the American Academy of Arts and Sciences, Council on Foreign Relations, American Public Health Association, National Academy of Medicine, National Medical Association, and American Academy of Pediatrics. A recipient of numerous awards, Helene has authored articles on global and domestic public health issues, poverty alleviation, gender equality, and wealth inequity. She has received 18 honorary degrees and holds faculty appointments at the University of Washington and Emory University. Helene earned a B.A. in psychology from Barnard College, an M.D. from the University of Pennsylvania, and an M.P.H. from Johns Hopkins University.

Sri Mulyani Indrawati is one of Indonesia's longest-serving and first female minister of finance, serving under three democratically elected presidents. Sri Mulyani led the country through major crises such as the global financial crisis and COVID-19 pandemic, while restoring fiscal discipline, achieving macroeconomic stability, restoring growth and reducing poverty - while elevating Indonesia's sovereign credit rating to investment grade. Sri Mulyani reformed and modernized the Ministry of Finance, strengthened public financial management–fighting corruption and building good governance and positioned Indonesia as a global leader in sustainable finance, including issuing the first sovereign Green Sukuk by an emerging economy. Internationally, Sri Mulyani has held senior leadership roles at the World Bank and the IMF and has advanced global cooperation through ASEAN and the G20. Sri Mulyani has received numerous international honors, including Best Minister in the World and recognition on Forbes' list of the World's 100 Most Powerful Women.

Ashish Dhawan is the founder and CEO of the Convergence Foundation (TCF), which is focused on accelerating India’s economic growth and development. He is also the chairperson of Ashoka University, a leading liberal arts university in India, and Central Square Foundation, a nonprofit foundation working to improve the quality of education for all children in India. TCF incubates nonprofits focused on creating system-wide impact in the areas of economic growth, equality of opportunity, and sustainability. Its current portfolio includes organizations working on jobs and investment, rule of law, governance and state capacity, economic empowerment of women, science and technology, air pollution, unlocking philanthropic capital, and improving the effectiveness of nonprofits. Before his second career as a philanthropist, Ashish was among India’s most successful private equity investors. He founded and ran ChrysCapital, the country’s leading private equity firm. Ashish graduated from Yale University and received his M.B.A. from Harvard Business School. He is also on the India Advisory Board of Harvard and a member of Yale’s Development Council. It’s a tremendous opportunity to work to improve the human condition across the world, nothing can be more important than that. - Ashish Dhawan Board Member Gates Foundation

Dr. Anita Zaidi oversees the foundation’s efforts to advance gender equality by including gender in all of the foundation’s global work. She seeks to ensure that women and girls in sub-Saharan Africa and South Asia can enjoy good health, make their own choices, earn their own money, and be leaders in their societies. The mission of the Gender Equality Division is a world in which everyone, everywhere, can thrive. Anita joined the foundation in 2014 to lead a team focused on vaccine development for people in the poorest parts of the world, disease surveillance to identify and address causes of death in children in the most underserved areas, and to significantly reduce the adverse consequences of diarrheal and enteric infections on children’s health in low and middle-income countries. She served as director of the foundation’s Enteric and Diarrheal Diseases team and Vaccine Development and Surveillance team until November 2022. In those roles, Anita led strategies resulting in the development and deployment of many lifesaving and disease-preventing vaccines, including rotavirus vaccines, typhoid conjugate vaccines, cholera vaccines, and novel oral polio vaccines. She also championed innovative work on behalf of low-income women and children, including the creation of the foundation’s Maternal, Newborn & Child Health upstream innovations strategy. She has led the Gender Equality Division since November 2020. Previously, Anita served as chair of the Department of Pediatrics and Child Health at the Aga Khan University (AKU) in Karachi, Pakistan, where she worked to reduce child mortality through the prevention and treatment of newborn illnesses and vaccine-preventable diseases. Anita earned a medical degree at AKU and completed further training at Duke University (pediatrics and microbiology), Boston Children’s Hospital, Harvard Medical School (pediatric infectious diseases), and the Harvard School of Public Health. She has published more than 200 research papers on vaccine-preventable diseases and newborn infections in resource-limited settings. In 2013, Anita became the first recipient of the US$1 million Caplow Children’s Prize for her pioneering work on bringing health services and wraparound care to mothers and children in low-income communities in Karachi. In 2014, she was nominated as a physician of the year by Medscape. In 2021, she was elected to the U.S. National Academy of Medicine for her global leadership in pediatric infectious disease research and capacity development for improving newborn and child survival in low- and middle-income countries.

Patrick leads the foundation’s efforts to ensure education works as a pathway to good jobs and upward mobility for far more Americans. Patrick joined the foundation in 2013 and has worked across several aspects of its U.S. education strategy, spanning K-12, pathways, and postsecondary education. His work has included partnering with institutions to redesign how they serve students, advancing new solutions and technologies, and strengthening the policy, communications, and data infrastructure that make lasting progress possible. Across these roles, Patrick has focused on how the different parts of the education continuum can work together to create more opportunities for students to thrive. Before joining the foundation, Patrick was a principal at Boston Consulting Group, where his work included supporting higher education institutions and K-12 systems through significant organizational and strategic change. Patrick holds an MBA from the Wharton School, a master's in educational leadership from the University of Pennsylvania, and a B.A. in Economics and Political Science from the University of North Carolina, where he was a Morehead Scholar.

Trevor Mundel leads the foundation’s efforts to develop high-impact interventions against the leading causes of death and disability in developing countries. He manages the foundation’s disease-specific R&D investments in HIV, Tuberculosis, Malaria, Pneumonia, Enteric and Diarrheal Diseases, and Neglected Tropical Diseases. He also manages cross-cutting product development programs, including Discovery & Translational Sciences, Innovative Technology Solutions, Integrated Development, and Vaccine Development & Surveillance. This work relies on close collaboration with an international network of grantees and partners. Prior to joining the foundation in 2011, Trevor was global head of development with Novartis and previously was involved in clinical research at Pfizer and Parke-Davis. Born and raised in South Africa, Trevor earned his bachelor’s and medical degrees from the University of the Witwatersrand in Johannesburg. He also studied mathematics, logic, and philosophy as a Rhodes Scholar at Oxford University, and he earned a Ph.D. in mathematics at the University of Chicago.

Kalpana Kochhar leads the foundation's work in international political and economic affairs, overseeing relationships with governments, intergovernmental organizations, advocates, and philanthropic partners worldwide. Kalpana previously served as director of the Development Policy and Finance team, a group of economists and development finance experts working to ensure that the foundation's global policy and advocacy work is informed by strong economic and financial analysis and insights, resonant with emerging trends, and connected to key decision-makers. Before joining the foundation in 2021, Kalpana spent 33 years at the International Monetary Fund (IMF), where her most recent position was director of the Human Resources Department. She also served as deputy director of the Asia and Pacific Department, working on programs and issues related to India, China, Korea, Japan, and several other Asian countries, and as deputy director of the Strategy, Policy, and Review Department, where she launched the IMF's work on gender and women's economic empowerment. From 2010 to 2012, she was seconded to the World Bank as its chief economist for the South Asia region. Kalpana's research interests and publications have focused on emerging markets, including India and China; jobs and inclusive growth; gender and inequality issues; structural reforms; and regional integration in South Asia. She has an M.A. and Ph.D. in economics from Brown University and an M.A. in economics from the Delhi School of Economics in India. She has a B.A in economics from Madras University in India.

Hari Menon leads the foundation's Global Growth & Opportunity Division, which includes the Agricultural Development, Digital Public Infrastructure, Global Education, Inclusive Financial Systems, Nutrition, and Water, Sanitation & Hygiene programs. These programs work to strengthen food security and improve incomes so millions of families can break free from poverty and more low-income countries in sub-Saharan Africa and South Asia can get on a path to prosperity. They support greater productivity on smallholder farms; expanded access to high-quality digital public infrastructure, including payment systems; improved foundational reading and math skills among children; development of large-scale food fortification systems; and delivery of innovative sanitation products and services. Before assuming his current role, Hari led the India office, overseeing the foundation's work in South and Southeast Asia spanning family health, nutrition, sanitation, digital financial inclusion, agriculture, and women's economic empowerment. These efforts, carried out in close collaboration with governments, local and global nonprofits, philanthropies, community groups, researchers, and the private sector, have contributed to progress toward India's national health and development goals and strengthened the foundation's partnerships in countries including Singapore, Indonesia, and Sri Lanka. Hari's earlier roles at the foundation included working on a range of public health efforts, particularly in maternal and child health and HIV prevention; leading policy, advocacy, and communications for programs in the Global Health, Global Development, and Global Growth & Opportunity divisions; and leading the foundation's policy work, government relations, and philanthropic partnerships in South and Southeast Asia. Hari has been at the foundation since 2004, with a brief stint (2011–2013) outside the organization as a strategic adviser to philanthropist Rohini Nilekani. Earlier in his career, Hari worked in the consumer goods and information technology sectors for companies including Colgate Palmolive and Infosys Technologies. Hari has a graduate degree in business management from XLRI – Xavier School of Management, Jamshedpur, and a bachelor's degree in mechanical engineering from the Faculty of Engineering and Technology, Jamia Millia Islamia, Delhi.

Dr. Chris Elias leads the foundation’s efforts to strengthen the systems that make health care more accessible, equitable, and effective. The teams he oversees include Polio, Immunization, Emergency Response, Global Health Agencies and Funds, and Exemplars in Global Health. Across these areas, he focuses on partnership and system-level innovation—helping countries and global partners design lasting solutions that improve health outcomes for all. Before joining the Gates Foundation in 2012, Chris was president and CEO of PATH, an international nonprofit organization that works to advance global health through partnership, innovation, and evidence-driven approaches. Chris has an M.D. from Creighton University, where he later received an honorary doctorate, and an MPH from the University of Washington, where he was a fellow in the Robert Wood Johnson Clinical Scholars Program. He completed his residency in internal medicine at the University of California, San Francisco. He also received an honorary doctorate from the University of Pittsburgh. Chris is a member of the National Academy of Medicine.

June Yoshinari Davis leads the foundation's people-centered strategies across talent, culture, and organizational effectiveness, which includes human resources and diversity, equity, and inclusion. She joined the foundation in 2019 as director of strategy, planning, and management in the U.S. Program and chief of staff to the program's president. Before assuming her current role, she served as chief diversity, equity, and inclusion officer. With more than 20 years of experience spanning human resources, talent strategy, and organizational transformation, June has led high-impact people initiatives across the corporate, nonprofit, and philanthropic sectors. At Cargill, she served as a strategic HR business leader for several of the company's global businesses, leading talent planning, leadership development, workforce engagement, and cultural transformation. She also spearheaded key initiatives to integrate diversity and inclusion practices, policies, and systems into a US$100 billion organization with more than 150,000 employees across 70-plus countries. June's professional background also includes serving as senior managing director for people development at Teach For America and holding key roles in digital transformation, organizational strategy, and business development at Nike and Target, ensuring that talent, structure, and culture supported sustained business growth. She brings all of this deep expertise to her role as chief people officer and the foundation's vision for strengthening organizational effectiveness, equitable and inclusive partnerships, and lasting global impact. June has an A.B. in psychology from Harvard University and an MBA from Harvard Business School.

Ankur Vora oversees the foundation's work across Africa and India—two regions central to the foundation's global mission—and leads enterprise-wide strategy, advising the chair and CEO on priorities, resource allocation, and major tradeoffs across the portfolio. Ankur works closely with governments and partners to ensure strategies turn into measurable improvements in people's lives, particularly in places facing the greatest health and development challenges. He also helps guide the foundation's long-term strategic direction, including advising senior leadership on priorities and planning toward its intended closure in 2045. He is known for a practical, results-oriented approach that values collaboration, shared accountability, and honest problem-solving. Before joining the foundation in 2013, Ankur was director of programs at the Children's Investment Fund Foundation, where he managed investments across Africa and South Asia. Earlier in his career, he was a principal at the Boston Consulting Group and a lecturer in economics at the University of Chicago. He holds a Ph.D. in economics from the University of Chicago and serves on the boards of Global Health Labs and the Gates Medical Research Institute. Ankur's commitment to social impact is deeply influenced by his upbringing in India, where he saw his parents commit their lives to helping others.

Shana Tarbell is the foundation’s chief operating officer, responsible for driving much of the daily operations that enable the organization’s mission. She leads a broad portfolio of teams—including Facilities, Events, Travel, Security, Information Technology, People, and a small team focused on strategic cross-operational initiatives—and works closely with operational leaders to ensure that all functions are integrated, efficient, and aligned around a shared purpose. Previously, Shana served as the foundation’s Chief Security Officer for six years, overseeing all aspects of staff safety and security, including information security. She joined the foundation in 2015 as a deputy director on the Security team, bringing deep expertise in risk management and global affairs. Before entering philanthropy, Shana spent 18 years at the U.S. Central Intelligence Agency, where she served on the Senior Intelligence Service and held leadership roles addressing complex global challenges. In 2015, she received the federal government’s Meritorious Presidential Rank Award, recognizing her sustained excellence at the senior executive level—an honor awarded to no more than 5% of federal career senior executives. She also received the CIA’s Distinguished Career Intelligence Medal for exceptional service.

Alex Reid leads communications for the foundation and is responsible for the strategic use of voice to amplify the foundation’s philanthropic role and impact. She oversees all communications work including reputation and risk management, region-specific communications, creative and brand strategies, leadership voice and employee communications. Previously, Alex served as chief communications officer at Gates Ventures, where she set communications strategy for Bill Gates. She also spent nearly a decade working at the foundation from 2010-2019. During this time Alex expanded the foundation’s communications across Europe, oversaw program advocacy and communications strategy, and led high-profile campaigns, including Goalkeepers. Alex was born and raised in London and attended the University of Nottingham, where she earned a B.A. in politics. She lives in Seattle with her husband, two daughters, and a very playful golden doodle dog.

Carolyn Ainslie oversees the foundation's financial planning and management functions—including accounting, financial analysis, investment strategy and processes, risk and assurance, business management, and the Strategic Investment Fund—as well as strategy and planning more generally. In this role, she ensures that the foundation's resources are allocated wisely, to maximize the impact of our program investments and operations around the world. Before joining the foundation in 2018, Carolyn worked for 10 years as vice president for finance and treasurer at Princeton University, where she was responsible for the central financial functions of the university and, as a member of the president's senior staff, served as a key partner on strategic university initiatives. Earlier, she spent 10 years as vice president for planning and budget at Cornell University. Carolyn has an MBA in finance from the University of Rochester and a bachelor's degree from Bucknell University.

Lauren W. Bright leads the foundation’s legal team and is responsible for all legal matters and activities pertaining to the foundation and its affiliate organizations. In this capacity, she advises the foundation’s trustees, CEO, senior leadership, and staff on legal issues, is a member of the Executive Leadership Team, and serves as corporate secretary to the foundation’s board of trustees. Lauren’s responsibilities include managing global legal affairs, governance, conflict of interest issues, and legal risk management. Before her appointment as CLO, she served as the foundation’s co-general counsel and director of the foundation’s Washington, D.C., office. Before joining the foundation in 2005, Lauren worked at the law firm Pillsbury Winthrop Shaw Pittman, where she served nonprofit clients on a variety of legal issues, including governance, tax exemption, transactions, mergers, and legislative and regulatory issues. Over the course of her career, she has represented institutions and companies before the U.S. Congress and administrative agencies regarding federal education policies and programs. Lauren is the author of several articles on association practice and management and is a frequent speaker on legal topics affecting nonprofit organizations. She has also been a guest lecturer on legal issues affecting tax-exempt organizations at the University of Washington Law School Graduate Tax Program. Lauren received a J.D. from Villanova University’s Charles Widger School of Law and a bachelor’s degree from Gettysburg College, where she currently serves as Chair of the Board of trustees.

Mark Suzman leads the Gates Foundation in advancing its mission to ensure that every person has the opportunity to live a healthy, productive life. He is deeply committed to building partnerships and fostering a culture that contributes to meaningful impact. He is currently guiding an historic 20-year acceleration of the foundation's work ahead of its planned closure in 2045. During this period, the foundation will spend US$200 billion toward its goal of ensuring that no mother or child dies of a preventable cause, the next generation grows up in a world without deadly infectious diseases, and hundreds of millions of people can break free from poverty, putting more countries on the path to prosperity. Mark's upbringing in apartheid South Africa instilled in him a desire to use the advantages afforded to him to help tackle injustice and inequality. He began his career as a journalist, writing for Johannesburg's The Star and the Financial Times . In 2000, Mark went to work for the United Nations, where he helped implement the Millennium Development Goals under the leadership of Secretary-General Kofi Annan. He also served as senior advisor for policy and strategic communications in the Office of the Secretary-General and as policy director at the United Nations Development Programme. Mark joined the Gates Foundation in 2007 as the director of global development policy, advocacy, and special initiatives. He went on to serve as managing director of the foundation's country offices and then president of the Global Policy & Advocacy Division and chief strategy officer of the foundation. In the latter role, he oversaw expansion of the foundation's work in India, China, Africa, and Europe and managed partnerships with governments, private philanthropies, and civil society organizations. Mark has a doctorate in international relations from Oxford University, where he was a Rhodes Scholar, and a bachelor's degree from Harvard University.

Thomas Stahura remains an emeritus associate at Ascend after leaving its day-to-day analyst role, according to founder Kirby Winfield’s current announcement. He joined as an analyst in 2024 after graduating in engineering from Purdue. He co-founded AI startups Quasi and Pondr and built Ascend’s AI-enabled portfolio tracking, deal-flow management and internal automation, contributed technical diligence, helped portfolio engineers and created the Token Talks newsletter.

Nate Bek is Senior Associate and Head of Content at Ascend, promoted by founder Kirby Winfield following his earlier Associate role. He previously covered Pacific Northwest startups as a GeekWire reporter. He studied at the University of Hawaii at Manoa and led Honolulu ice-cream business Lucy’s Lab Creamery, developing an interest in entrepreneurship through operating experiments and partnerships.

Jen Haller is Partner and Chief of Staff at Ascend. She supports portfolio founders and firm operations, drawing on experience helping Seattle startups grow, including Ascend portfolio company Attunely through its Series A. She has extensive civic and volunteer involvement and participated in the first COVID-19 vaccine clinical trial.

Kirby Winfield founded Seattle venture-capital firm Ascend in 2019 and serves as its Founding General Partner. He invests in pre-seed AI startups and helps founders navigate customers, recruiting and later-stage financing. Before investing he held operating roles in four startups with four exits, including two IPOs and two acquihires. His current issuer biography also identifies him as a director and investor in Bean Box since 2016.

Shamini Chandran is listed by SPRIM Global Investments as Administrative Assistant. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Janice Wong is listed by SPRIM Global Investments as Accountant. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Amudhan Arumugam is listed by SPRIM Global Investments as IT Manager. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Maddy Hoang is listed by SPRIM Global Investments as Investment Analyst. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Juan Palazón is listed by SPRIM Global Investments as Financial Controller. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Published name: Michael Jackson. This profile refers to Fabric Ventures; existing namesake records are preserved.

Tina Leung publishes Treasure Play as her affiliation and describes experience in game art and UI design.

PixAI is an AI creation platform operated by Mewtant in the United States and its Japanese entity Metanomaly. It helps artists and anime enthusiasts generate illustrations and original characters from text, edit uploaded images, change styles, finish sketches and upscale artwork. Users can choose community models and LoRAs, train or reuse creative setups, and publish work in a shared gallery. Its browser and mobile services combine generation tools with tutorials, contests and creator projects. PixAI Studio provides a visual workspace that connects image, video, text and audio generation and editing steps into production workflows. The platform also offers anime image-to-video tools and supports longer projects such as manga, visual novels, character IP and games.

Treasure Play is a technology company developing products that combine AI with user engagement and human collaboration. Its current website describes a new direction in intelligent work and human–AI collaboration, with further product details yet to be published. Its earlier launched platform helped game and app developers acquire users, monetize audiences and analyze activity through AI-generated quests and personalized rewards. It could use app event data to configure campaigns, generate missions and content, recommend improvements and automate bidding and quest optimization. Players received in-app or real-world rewards for completing milestones. The business began as Trailblazer Games, building blockchain games and the Eternal Dragons franchise, and announced its transition to Treasure Play in September 2024. Makers Fund continues to list it as an active portfolio company, and the current company website names Makers Fund, Play Ventures and Fabric Ventures as backers.

Alex Arias previously founded gaming data platform Omniata, acquired by King in 2017, and held leadership roles at King, EA and Microsoft.

Andreas Risberg previously worked on the growth and product development of Candy Crush games.

Bertrand Lamarque built and led technology teams at Playfish and EA.

Jiayu Liu is listed by Mewtant and describes his experience as engineering leadership and technical management.

Melike Özcan describes her background in product management, growth and engagement and publishes Treasure Play as her affiliation.

Raven Gao founded PixAI and leads its operator Mewtant; Stanford identified both roles at its June 2, 2026 AI and media startups event.

Rissa Cao is a Mewtant co-founder and operating executive with experience in product development, consumer software and data-driven growth.

Shoin Wolfe leads analytics, growth and design at Mewtant/PixAI. His own profile identifies the role beginning in March 2026; the exact starting day is undisclosed.

Healthcare adviser and former US Secretary of Health and Human Services, serving in government from 2018 to 2021.

Leads compliance and supports investment-firm legal matters.

Bioengineer with medical-sciences doctoral training supporting product development and commercialization.

Electrical engineer and integrated-circuit designer investing in semiconductor and photonics technologies.

Evaluates public and private biotechnology investments.

Provides executive support to the CEO’s office.

Technology R&D and venture investor supporting startup strategy and international growth.

Reconciles public and private holdings and records trading activity.

Physician-scientist evaluating biotechnology and healthcare investment opportunities.

Oversees research and development evaluation for healthcare investments.

Health-technology investor supporting early-stage companies through growth and exits.

Leads investor relations, capital formation and strategic business initiatives.

Physician and investor evaluating private and public biotechnology companies.

Evaluates therapeutics investment opportunities.

Supports limited partners, investor communications and capital formation; current Director title takes precedence over older Associate Director biography wording.

Founded Foresite Capital in 2011 and leads healthcare company investment and creation at the intersection of biology, AI and engineering.

Provides executive administration for investment professionals.

Electrical and biomedical engineering professional supporting deep-tech founders.

Develops and maintains investment-firm compliance processes.

Leads Foresite Labs scientific strategy, company creation and portfolio development in AI and biomedicine; published as Foresite Capital Venture Partner.

Provides executive assistance to the investment team.

Supports the CEO’s office.

Provides executive support to investment and investor-relations leadership.

Foresite Labs operating partner building companies at the intersection of AI and biotechnology; published as Foresite Capital Venture Partner.

Supports executive administration and operations.

Advises on sourcing, diligence, portfolio oversight and healthcare company incubation.

Monitors private investments and leads portfolio valuation; current Director title supersedes older Manager wording in the biography.

Leads human resources; current Director title supersedes older Senior Associate wording in the biography.

Advises the life-sciences investment team.

Supports companies commercializing research and innovation.

Healthcare adviser supporting medicine discovery, development and commercialization.

Leads investor relations and business-development work.

Former photonics startup CEO supporting technology-driven companies.

Leads therapeutics investing across incubation, private financings and public markets.

Foresite Labs venture partner launching and building incubated companies while supporting Foresite Capital.

Evaluates technologies in chemistry, energy and novel memory devices.

Supports administration and internal processes.

Repeat entrepreneur supporting technical feasibility, differentiation and scaling.

Leads clinical development strategy for Foresite Labs incubations and supports Foresite Capital scientific diligence as Venture Partner.

Evaluates investments through diligence and financial modeling.

Venture and growth-company legal adviser; founding partner and chairman emeritus of Gunderson Dettmer, an external legal firm.

Supports fund transactions and legal matters.

Invests in life sciences and healthcare technology; previously developed healthcare partnerships at Verily.

Sources and evaluates healthcare technology and services investments.

Reviews fund financial activity, reconciliations and quarterly reporting.

Coordinates accounting, capital calls, distributions and cash management.

Supports portfolio companies with positioning and communications.

Leads Foresite Labs therapeutics strategy and company creation; published as Foresite Capital Venture Partner.

Healthcare venture partner with earlier leadership in GRAIL’s operations and commercialization.

AI and life-sciences adviser; co-founder and CEO of the distinct Foresite Labs company-building platform.

Evaluates biotechnology investment opportunities.

Built a distribution business to USD18 million in two years and has experience in consumer goods, supply chains and private equity.

SHOPLINE president and technology executive. Provides ecommerce infrastructure and serves on F&F Ventures’ investment committee.

Consumer packaged goods entrepreneur with two ecommerce exits and co-founder of Protein Waffles.

F&F Ventures is the venture investment arm of the Founders & Funders community. It invests from pre-seed through Series A in consumer goods businesses and ecommerce-enabling technology, sourcing founders through the community’s events and relationships across more than a dozen cities. The firm combines investment capital with operating experience, distribution and founder networks, purchase-order financing and commerce infrastructure. Its USD10 million ecommerce fund operates with SHOPLINE as venture partner and anchor; a separate USD100 million consumer goods and technology fund is fundraising and currently uses SPVs.

Founded Founders & Funders, built and sold a consumer business to private equity, and has made more than 40 angel investments.

Chang Chu Chuen is listed by SPRIM Global Investments as Senior Investment Analyst. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Chong Wee Khoo is listed by SPRIM Global Investments as Director of Accounting & Compliance. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Hartini Ismail is listed by SPRIM Global Investments as Group HR Manager. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Daniel Martinez is listed by SPRIM Global Investments as VP Clinical Trials Financing. The source establishes the published group affiliation; no additional employer or personal investment is inferred.

Adele Hosseini is listed by SPRIM Global Investments as Venture Director. The published venture affiliation does not establish full-time employment.

Joti Marango is listed by SPRIM Global Investments as Venture Partner. The published venture affiliation does not establish full-time employment.

Igor Matushansky is listed by SPRIM Global Investments as Venture Partner. The published venture affiliation does not establish full-time employment.

Nick Srikanth is listed by SPRIM Global Investments as Venture Partner. The published venture affiliation does not establish full-time employment.

Elizabeth Wang is listed by SPRIM Global Investments as TrialCap, Director, Credit Structuring. This capacity belongs to SGI’s clinical-trial financing platform.

Guillaume Pfefer is listed by SPRIM Global Investments as Venture Partner. The published venture affiliation does not establish full-time employment.

Sylvain Labattu is listed by SPRIM Global Investments as Managing Director, TrialCap. This capacity belongs to SGI’s clinical-trial financing platform.

Gonzalo Rubio is listed by SPRIM Global Investments as TrialCap, Partner. This capacity belongs to SGI’s clinical-trial financing platform.

Al Hummel is an SGI senior partner. His own biography describes healthcare operating and capital-markets experience, including leadership at Obagi Medical Products, Cobrek Pharmaceuticals and Watson Pharmaceuticals. These outside positions are historical career context.

Thomas Fratacci is published as partner and group CFO in SGI’s current team. His own biography describes group finance, financing-round and exit work, with earlier financial audit and WPP/Kantar executive experience.

Ivan Jarry is SGI’s co-founder and managing partner. His own biography describes developing SPRIM’s international healthcare operations and overseeing SGI’s R&D-services portfolio since2015, with business-management training at EDHEC.

Michael Shleifer is SGI’s co-founder and managing partner. His own biography describes doctoral training in pharmacology, earlier work at L’Oréal, co-founding the SPRIM operating business and developing SGI’s biotech and clinical-trial financing strategies. The consulting business and investment firm chronologies are distinguished.

SPRIM Global Investments (SGI), identified in issuer financing announcements as SPRIM Global Investments Pte. Ltd., is a privately held Singapore-based life-sciences investment firm. It backs clinical-stage biotechnology, medical devices, healthcare software and pharmaceutical R&D services, using equity and structured financing together with clinical operating expertise. Its public team includes core investment partners, venture partners, TrialCap clinical-trial finance specialists and group operational staff. The own directory dates the investment firm to2008, while a founder biography describes deployment of its current investing strategies from2015; these source chronologies are kept distinct from the SPRIM consulting business established in2001. SGI is distinguished from SPRIM PRO consulting/CRO services, portfolio operating companies and individual fund vehicles. Its clinical-stage portfolio includes auditory science, neurodevelopmental precision medicine, epilepsy monitoring, neuromodulation and blood-brain-barrier research. Announced financing capacity and joint ventures are not automatically completed LP fund raises.

Alexander Sturgis is named by the University of Oxford as Director of Ashmolean Museum in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Alison MacDonald is named by the University of Oxford as Interim Head, Department for Continuing Education in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Gavin Svenson is named by the University of Oxford as Director of Oxford University Museum of Natural History in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Laura van Broekhoven is named by the University of Oxford as Director of Pitt Rivers Museum in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Lindsay Rudge is named by the University of Oxford as Divisional Registrar and Chief Operating Officer, Gardens, Libraries and Museums in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Silke Ackermann is named by the University of Oxford as Director of History of Science Museum in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Simon Hiscock is named by the University of Oxford as Director of Botanic Garden in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Andrew Mackie is named by the University of Oxford as Director of Legal Services and General Counsel in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

David White is named by the University of Oxford as Chief Digital and Information Officer in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Liesl Elder is named by the University of Oxford as Chief Development and Alumni Engagement Officer in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Richard Ovenden is named by the University of Oxford as Head of Gardens, Libraries and Museums; Bodley’s Librarian in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Saira Shaikh is named by the University of Oxford as Academic Registrar in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Simon Boddie is named by the University of Oxford as Chief Financial Officer in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Simon Boddie is an Oxford University Innovation non-executive director and University of Oxford Chief Financial Officer. His current OUI biography dates his Oxford Science Enterprises representative board service from2021 to early2026 and Learning Technologies Group directorship to2025. Earlier work included 15 years on boards of FTSE250 businesses.

Tim Soutphommasane is named by the University of Oxford as Chief Diversity Officer in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Bríd Cronin is named by the University of Oxford as Divisional Registrar, Social Sciences in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Dan Grimley is named by the University of Oxford as Head of Humanities Division in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Oxford’s own Humanities leadership profile confirms that Daniel (Dan) Grimley heads the division and oversees its academic strategy, planning and financial management; he is a musicologist.

Gillian Hamnett is named by the University of Oxford as Deputy Academic Registrar, Strategic Business Change; Interim Proctors’ Office in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Jackie Hoyle is named by the University of Oxford as Deputy Academic Registrar, Education Services in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

James Naismith is named by the University of Oxford as Head of Mathematical, Physical and Life Sciences Division in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Oxford’s own MPLS profile identifies James (Jim) Naismith as the current division head, with published research in molecular structure, enzymes and biological chemistry. This living Oxford academic is distinct from the historical basketball inventor.

Timothy Power is named by the University of Oxford as Head of Social Sciences Division in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks. Oxford’s own current Social Sciences biography describes a comparative political scientist researching democratization and political institutions in Latin America, especially Brazil; he leads the division and participates in University Council.

Alex Vincent is named by the University of Oxford as Divisional Registrar, Humanities in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Antony Willott is named by the University of Oxford as Director of Planning and Council Secretariat in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Chris Price is named by the University of Oxford as Divisional Registrar, Medical Sciences in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Iain Critchlow is named by the University of Oxford as Interim Director of Estates in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Lorna Thomson is named by the University of Oxford as Director of Research Services in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Markos Koumaditis is named by the University of Oxford as Director of Human Resources in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Tracy Gale is named by the University of Oxford as Divisional Registrar, Mathematical, Physical and Life Sciences in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

James Colman is named by the University of Oxford as Director of Communications in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Oxford’s October 2026 officer roster explicitly names Lionel Tarassenko as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation President of Reuben College; biomedical-engineering and machine-learning researcher. This university governance role does not establish personal cash investments or employment at a venture fund.

Lukasz Bohdan is named by the University of Oxford as Director of Assurance in its senior reporting chart current July 24, 2026. The affiliation is dated to that primary publication rather than assuming an unverified exact appointment day or adding all university employees. This institutional leadership role does not imply personal venture checks.

Oxford’s October 2026 officer roster explicitly names Aziz Sheikh as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Head of the Nuffield Department of Primary Care Health Sciences. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Nigel Shadbolt as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Principal of Jesus College; artificial-intelligence and computer-science researcher. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Jennifer Payne as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Warden of Merton College. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Jonathan Michie as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation President of Kellogg College. This university governance role does not establish personal cash investments or employment at a venture fund.

Muneeb Ahsan is named as a software developer and data analyst in the older English company directory. This is a dated published relationship to Portabiles HealthCare Technologies; the newer German roster does not establish a current operational appointment. The directory provides a logo placeholder rather than a genuine portrait, so no substitute headshot is uploaded.

Nicole Pohlschmidt is named as Head of Digital Medical Support in the older English company directory. The2024 financing post also references her account but does not define a separate current appointment. The company directory uses a logo placeholder for her image; this is retained as a genuine portrait gap, while current employment dates and wider credentials remain unclaimed.

Oxford’s October 2026 officer roster explicitly names Helen Moore as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation President of Corpus Christi College. This university governance role does not establish personal cash investments or employment at a venture fund. The academic is distinct from the existing same-name venture-investment professional.

Malte Ollenschläger is listed as a software developer and data analyst in the older English Portabiles HealthCare Technologies directory. His documented function concerns software and analysis supporting the company’s wearable-health technology. Present employment, broader biography and exact appointment dates require further primary material.

Oxford’s October 2026 officer roster explicitly names Michael Jacobs as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Warden of Keble College. This university governance role does not establish personal cash investments or employment at a venture fund.

Oxford’s October 2026 officer roster explicitly names Sarah Foot as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Dean of Christ Church. This university governance role does not establish personal cash investments or employment at a venture fund.

Anselm Hochschild is named as a software developer and data analyst in the older English company directory. This establishes a published operational relationship to the digital-health business; it does not establish his present employment or any personal financing contribution. The older publication is retained with a current-status qualification.

Oxford’s October 2026 officer roster explicitly names Judith Buchanan as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation Master of St Peter’s College. This university governance role does not establish personal cash investments or employment at a venture fund.

Karthik Ayyalasomayajula is listed as a software developer and data analyst in Portabiles HealthCare Technologies’ older English directory. The published function supports digital products and data analysis in a wearable gait-analysis business. Current appointment status and dates remain undisclosed rather than inferred from an older live web page.

Published as Interim Registrar in the July 2026 direct-report chart and current October university officer roster. The interim appointment is distinguished from previous Deputy Registrar and predecessor Registrar posts.

Oxford’s October 2026 officer roster explicitly names Sue Black as a Pro-Vice-Chancellor without portfolio, alongside the published affiliation President of St John’s College. This university governance role does not establish personal cash investments or employment at a venture fund.

Professor of Cognitive Neuroscience studying brain plasticity and recovery after injury; former 2015–2025 Wellcome Centre for Integrative Neuroimaging director. Leads cross-university initiatives including the proposed Warneford Park brain and mental-health campus.

Susanne Sand is named as a project assistant in the older English company directory. Her relationship is qualified to that published roster, since the newer German page does not confirm a current operational appointment. The company substitutes a brand logo for her directory image; no portrait is fabricated or represented as available.

Hayat Koubaa is named as Head of Business and Product Marketing in the older English Portabiles HealthCare Technologies directory. This documents a business and product-marketing role in the digital-health company; the page’s2023 metadata and newer roster differences are retained. Current employment, qualifications and appointment dates require further primary evidence.

Physics and materials researcher specializing in solid-state nuclear magnetic resonance; formerly led Lancaster and Southampton universities. Began the Oxford portfolio in June 2026, without an inferred exact day.

Oxford Vesuvius Professor of Materials researching batteries, additive manufacturing and power-generation alloys; previously headed the Materials Department and is a non-executive director of Oxford University Innovation. Distinct from the same-name Outlier Ventures analyst. The academic is distinct from the existing same-name venture-investment professional.

Stefan Schulz is named as head of development in the older Portabiles HealthCare Technologies English directory. The published function relates to development of the company’s digital and sensor-based products. Current appointment status, career history and exact dates are not provided by the newer directory and are not invented.

Professor of Politics and former DPIR head, researching comparative political economy and migrant remittances. The latest July 2026 organizational chart gives appointment start September 2, 2026; current October officer page confirms appointment.

Chantal Herberz is identified as Head of Product Strategy in the older English company directory and appears as the author of primary issuer financing and innovation-program announcements. The company develops wearable and digital services for movement-disorder care. Her directory role is qualified to the older publication; a later outside affiliation is not overwritten or treated as simultaneous company employment without evidence.

Oxford statutory professor of Biomedical Engineering, researching therapeutic ultrasound and drug delivery; co-founded OrganOx, OxSonics and OrthoSon. Began the innovation portfolio in April 2026; exact day undisclosed. Constantin Coussios serves as an Oxford University Innovation non-executive director and University of Oxford Pro-Vice-Chancellor for Innovation. He holds Oxford’s statutory biomedical-engineering chair and Cambridge MEng/PhD degrees. His academic entrepreneurship includes OrganOx, OxSonics and OrthoSon, developing technologies including therapeutic ultrasound and medical devices.

Professor of Forced Migration and International Affairs and co-founder of the Refugee-Led Research Hub. Began this university portfolio in June 2025; exact day undisclosed.

Julius Hannink is named as an algorithm specialist in Portabiles HealthCare Technologies’ older English directory. His documented company function concerns analytical methods supporting sensor-based movement analysis. The directory remains publicly accessible but was last dated2023 and differs from the newer German roster, so present employment and precise start/end dates are unconfirmed.

Professor of English whose research concerns eighteenth- and nineteenth-century literature. Oversees teaching, learning, admissions and student support.

Jörg Stein is identified as CFO in the older English company directory and2024 financing announcement. His own M&P consulting announcement describes support for founder Ralph Steidl’s team as CFO from spring2020, and a current Radiomics biography calls the role interim CFO. He has medical-device financing, strategy and business-development experience; his latest exact appointment status requires confirmation against the newer German company directory, which omits this role.

Professor of Anaesthetic Neuroscience, researching pain perception and anaesthetic consciousness with advanced neuroimaging; former Merton Warden and founding FMRIB scientist. Irene Tracey is listed by the Lundbeck Foundation as Member of the Board. Foundation board member elected2026 and research/prize committee member. Oxford Vice-Chancellor and anaesthetic-neuroscience professor with neuroimaging/pain research and scientific-leadership experience; previously Brain Prize selection-committee member.

Sabine Stallforth is a neurology specialist identified in the University Hospital Erlangen care-partner section of the Portabiles HealthCare Technologies directory. Her published relationship supports ParkinsonGo’s clinical service. She is recorded as an external clinical partner rather than presumed company staff; additional current hospital titles are not inferred.

Teresa Greinwalder provides nurse-service support through University Hospital Erlangen, identified by the company as a care partner for ParkinsonGo. The own directory places her under the external hospital-partner section, rather than company management. This relationship concerns service delivery and is not represented as direct company employment or a financing participation.

Former UK foreign secretary and Oxford PPE alumnus; elected November 2024 and admitted to university office on February 19, 2025.

The University of Oxford is the statutory civil corporation legally named The Chancellor Masters and Scholars of the University of Oxford, formally incorporated by the 1571 Act for Incorporation of Both Universities. It is an exempt charity under the Charities Act 2011, regulated principally by the Office for Students, and has no Royal Charter or Charity Commission registration number. Its legal, academic and investment identity is distinct from the technology-transfer subsidiary Oxford University Innovation, the independent investment company Oxford Science Enterprises, Oxford University Innovation Fund and Oxford Seed Fund. Oxford conducts and translates research in artificial intelligence, computing, engineering, quantum technologies, biomedical science and neuroscience. Its October 2026 senior officer roster includes Chancellor William Hague, Vice-Chancellor and anaesthetic-neuroscience professor Irene Tracey, and seven portfolio Pro-Vice-Chancellors. Heidi Johansen-Berg leads Strategic Initiatives and researches brain plasticity; biomedical engineer Constantin Coussios leads Innovation. The profile covers published university senior officers and the dated July 24, 2026 leadership reporting chart, with September 2026 appointments reconciled against the current roster, rather than every university employee. The University can own founding equity and make actual follow-on company investments. Its policy generally allocates founding equity 80% to the founding team and 20% to the University, with some 90:10 cases, before fundraising and without anti-dilution protection; this policy is not proof of a particular company cash check or an unchanged present ownership percentage. Oxford Science Enterprises receives part of applicable university founding stakes under a separate partnership. Oxford Endovascular explicitly names the University itself as an actual following investor in its April 2021 Series A and May 2024 Series A+ rounds. Those issuer-confirmed investments are recorded under this institutional identity without duplicate subsidiary or personal-officer attribution. University budgets, endowment assets, spinout portfolio valuation, fundraising across its spinout ecosystem and grants received for academic research are not private LP venture-fund closes. No undisclosed institution ticket or blanket cash portfolio is inferred.

Björn Eskofier is a co-founder and scientific advisor of Portabiles HealthCare Technologies. The company combines machine learning, wearable movement data and neurological-care research. His own2024 public financing post corroborates a staged equity fundraising and his company affiliation, while current own company material identifies his scientific advisory role. Personal cash participation is not inferred from announcing institutional funding.

Jürgen Winkler is a medical advisor named by Portabiles HealthCare Technologies in its current German directory. His advisory relationship is associated with neurological care and the company’s gait-analysis services for movement disorders. The published directory does not call him a company co-founder, so that title is not inferred. Additional appointments and personal investment amounts require separate primary proof.

Jochen Klucken is a medical co-founder and advisor of Portabiles HealthCare Technologies. The own current directory identifies his medical advisory capacity; the company’s origin links neurological research with wearable gait measurement and data analytics. His contribution is qualified as advisory involvement, without inferring ownership percentages, clinical efficacy or additional current university appointments.

Portabiles HealthCare Technologies GmbH is an Erlangen, Germany digital-health company developing sensor-based gait analysis and hybrid care for people with Parkinson’s disease. It emerged in late2016 from research with University Hospital Erlangen and Friedrich-Alexander University Erlangen-Nuremberg’s machine-learning and data-analytics laboratory. Its ParkinsonGo service combines wearable sensors, a smartphone app, personalized movement exercises and support from qualified nurses and neurologists; its Mobile GaitLab and Stepmetric products support gait measurement in clinical and related settings. Algorithms analyze movement and patient-reported information to support clinical decision making and ongoing monitoring. These are care-support tools rather than a claimed cure or replacement for professional treatment. The exact operating entity is registered at Fürth under HRB17289, VATDE310040104, represented by founder and CEO Ralph Steidl at Henkestraße91,91052Erlangen. It is legally distinct from Portabiles GmbH, HRB14816/VATDE297736960, which operates portabiles.de at the same address with different managing directors; their funding and staff are not merged. Current own German directory identifies four management/advisory people and two external University Hospital Erlangen care partners; an older English directory remains live with additional staff whose current appointment status is qualified. EIT Health describes ParkinsonGo as a ClassI CE-marked device under MDR, and the company reports FDA registration with 510(k) exemption. This is not a claim of FDA clearance or approval. Product research, reimbursement arrangements and intended international projects are distinguished from proven outcomes and regulatory authorizations. EIT Health has supported the company through its2020 Start-up Rescue Instrument, later financing and digital-health innovation programs; staged fundraises and total-round disclosures are qualified separately to avoid adding cumulative or approximate amounts as fresh cash.

Ralph Steidl founded Portabiles HealthCare Technologies and leads the company as CEO. Its current legal notice names him as the authorized representative. His work connects the company’s wearable gait-analysis technology with ParkinsonGo’s clinical and nurse-supported service. The company grew from university and hospital research into a digital-health business; institutional financing is not treated as a personal investment.

We Venture Capital is the evergreen corporate venture investment arm of Werfen, the specialized diagnostics group. It invests globally in diagnostics startups, biotechnology, and digital tools that support diagnostic workflows and clinical decisions. Its published strategy focuses primarily on Series A, with selective seed and Series B investments in companies approaching market entry or preparing to scale. The team supports portfolio companies through follow-on capital, board involvement and access to Werfen’s scientific, technical, commercial and international networks. Its investments include genomic data analysis, early cancer detection, therapeutic drug monitoring, single-molecule protein sequencing and connected patient monitoring.

Life sciences investor with experience supporting early-stage funds at BioCity and working with portfolio boards. Previously held commercial roles at venture-backed startups and studied analytical chemistry.

Physician and pharmaceutical professional with experience as an emergency physician and medical manager in oncology. Holds an ESADE MBA and sources and analyzes investments for We Venture Capital.

David Chang is the ophthalmologist and past president of the American Society of Cataract and Refractive Surgery named by Iantrek as an adviser. He is distinct from the biotechnology executive DavidChang already in the database.

Iqbal “Ike” Ahmed is a glaucoma surgeon named on Iantrek’s testimonial panel. The panel labels him Chief Medical Officer, but the company’s explicit2025leadership announcement and current board identify Sean Ianchulev as CMO. Ahmed is recorded as a qualified clinical-advisory affiliation, without asserting a simultaneous current executiveappointment.

Stephen Bloch is a current Iantrek board observer and Canaan Partners general partner. OlderSECfilings list director; current company observer designation is recorded without guessing transitiondate.

Andrew Corley is a current Iantrek board observer and is identified by the company as co-founder of Flying-L Partners. OlderSECfilings list director; current own directory observer takes precedence without inventing transitiondate.

Otos Health develops an integrated platform for hearing and cognitive health assessment. Its Otoscreen system combines a diagnostic device, automated assessments, software and clinical algorithms so nonspecialists can perform hearing tests in primary care. The platform connects early risk detection, clinical triage, patient monitoring and follow-up across primary care, audiology, ENT and other care settings. It is advancing clinical validation and pilot programs in Europe and preparing for deployment in the United States. The company emerged from Aalto University research and aims to make hearing care easier to access while improving understanding of the relationship between hearing and cognitive health.

Solid IO develops patient-specific tumor-on-chip technology for immuno-oncology research and drug development. Its platform recreates a patient’s tumor microenvironment, including immune interactions, and combines these biological models with bioengineering and AI to study responses to immunotherapies and combination treatments. It serves pharmaceutical and biotechnology companies, cancer researchers and clinical research partners seeking better preclinical models, biomarkers and patient stratification. The technology is currently for research use only; the company is validating it with partners and developing future clinical applications. Solid IO is a University of Helsinki spinout operating through Finnish company Solid Immuno-Oncology Oy.

Advises on translational immuno-oncology and ex vivo platforms, with academic research experience at MIT, Harvard Medical School, Dana-Farber Cancer Institute and Massachusetts General Hospital.

MSc in Translational Medicine and PhD candidate.

Advises on ecosystem strategy, drawing on pharmaceutical strategy and consulting experience across pharma, medical technology, payers and providers.

Advises on global pharmaceutical strategy and commercialization, with experience translating clinical technologies to commercial use at Roche, Novartis and MSD.

Advises on commercial strategy and global market access, with 15 years supporting international expansion, adoption and reimbursement of healthcare technologies.

MSc in Cell Technology, class of 2026.

MSc in Molecular Biosciences and BEng in Biotechnology.

Cancer researcher with more than 20 years of experience, including Harvard Medical School and Dana-Farber Cancer Institute; specializes in translational cancer biology, functional precision medicine and patient-derived cancer models.

PhD in Biochemistry.

PhD in Biochemistry with nearly 30 years of pharmaceutical and biotechnology company development experience; former longtime CEO of DelSiTech and co-founder of Laurantis Pharma and BioCis Pharma.

Healthcare executive with more than 20 years of experience in growth, multisite operations and mergers and acquisitions across medical devices, specialty care and consumer health.

Healthcare executive with 30 years of experience in business development, commercialization and company growth and transformation; MSc in health, BSc in pharmacy and EMBA.

Organ-on-chip and microphysiological systems researcher, head of the 3R-Center Tübingen and professor at the Natural and Medical Sciences Institute and University of Tübingen.

BSc in Cell and Molecular Biology.

MD and PhD, ENT specialist and otologist with more than 17 years of clinical and academic experience.

Advises on regulatory affairs and clinical laboratories, drawing on almost three decades at Mayo Clinic and experience in laboratory-developed tests, laboratory standards and FDA pathways.

MBA with experience in project coordination, operations, customer relationships, sales and marketing across international markets.

Clinical engineer in audiology with a PhD and more than 15 years of clinical and academic experience in acoustics, audiology and electrical engineering.

Aalto University MSc with 15 years of product development experience in medical, security and climate technology, including Philips Medical Systems MR Finland and KaVo Kerr.

Jeffry Weinhuff is a current Iantrek board member and Visionary Ventures partner. IantrekSECfilings use JeffryK.Weinhuff and JeffreyK.Weinhuff name variants; the company directory and matching ophthalmic investment affiliation establish one person.

Adam Szaronos is Iantrek’s chief executive officer and a board member, appointed inFebruary2025 to lead commercialisation of its glaucoma surgical products. He succeeded founder Sean Ianchulev, who retained chairman/CMO responsibilities.

Sean Ianchulev founded Iantrek and remains its chairman and chief medical officer following Adam Szaronos’s2025CEOappointment. He is a professor of ophthalmology at New York Eye and Ear of Mount Sinai and an ophthalmic surgical-device innovator. CompanySECfilings use Tsontcho Ianchulev for the corresponding founder/executive; no separate person is inferred from the formal-name variant.

Pharmacologist with pharmaceutical drug-discovery experience, including departmental leadership at Sanofi. Cilcare’s biography names him head of drug discovery and preclinical research at Fraunhofer ITMP.

Pharmacology expert in otologic and neurologic diseases, previously Chief Scientific Officer at Otonomy. Has worked on local inner-ear drug-delivery technologies and hearing-therapy development.

Quality-systems manager responsible for Cilcare quality processes, audits and continuous improvement. Previously worked as a quality engineer in dermocosmetics, coordinating subcontractor specifications and audit procedures.

Data scientist specializing in pharmacometrics, machine learning and predictive tools for auditory datasets. Previously worked in Sanofi’s clinical pharmacometrics and programming team on pharmacokinetic simulations and neural-network methods.

Clinical audiologist and researcher at Ear Science Institute Australia studying the relationship between hearing loss and cognitive impairment. Her published work includes the HearCog hearing-intervention trial.

ENT surgeon and neuroscience researcher at CHU Montpellier, specializing in hearing-loss treatment and cochlear implants. Participates in Cilcare clinical research and studies auditory therapeutic strategies.

Data-science and AI engineer leading Cilcare’s data architecture and analysis of preclinical and clinical auditory measurements. Works on digital auditory signatures and biomarker methods for precision medicine.

Physician, HEC graduate and healthcare strategy consultant with pharmaceutical and biotech experience. Advises on market access, real-world evidence, health authorities and the transition from R&D to commercial operations.

ENT surgeon and auditory researcher at CHU Bicêtre in Paris. Studies auditory-nerve regeneration and cochlear synaptopathy, including preclinical synapse-repair approaches and CIL001 development.

Audiologist and auditory-neuroscience researcher whose work addresses hearing loss, tinnitus and associated cognitive conditions. His Cilcare biography describes teaching at Worcester State University and patient-care work in hearing organizations.

Administration and HR manager supporting Cilcare employee relations, administrative processes and workplace coordination. His background includes education, tourism and multilingual cross-cultural communication.

Full-stack developer building Cilcare clinical-research dashboards and secure internal applications. Previously developed JavaScript applications at Smile, including work for Suez.

Pharmacist and innovation-management professional coordinating drug-development projects and clinical-trial regulatory submissions. Previously worked on medical-care licensing at Pierre Fabre and innovation commercialization at CHU Montpellier.

Infrastructure and real-estate operations leader involved in Cilcare laboratory development since its founding. Previously directed quality at Cilcare and worked in pharmacology at Sanofi; oversees worksites, IT infrastructure and compliance.

Pharmaceutical strategy and clinical-development executive appointed to Cilcare’s board on December 2, 2024. The January 2025 announcement describes her Catalyst Pharmaceuticals chief strategy role and earlier Sanofi, Abbott, Covance and Neurovision experience; later tenure has not been independently confirmed.

Auditory researcher at the State University of New York at Buffalo, with work spanning tinnitus, neural plasticity, ototoxicity and age-related hearing loss. Advises Cilcare on preclinical hearing models and their translation to clinical research.

Endocrinologist and diabetologist who co-founded France’s Institute of Diabetology and Nutrition of the Centre. Contributed to Cilcare’s DIAMANT observational study of auditory profiles in diabetic patients.

Finance manager responsible for Cilcare budgeting, financial analysis, cash-flow planning and administrative coordination. Her company biography describes more than twenty-five years of financial-management experience.

Auditory scientist and clinical audiologist researching cochlear synaptopathy and measures of hidden hearing loss. Combines animal-model research with human electrocochleography and clinical auditory assessments.

AI and machine-learning professional and managing director of AltGR. Cilcare names him an external acting Chief Data Officer overseeing data strategy, databases and auditory-signature projects.

Auditory researcher specializing in cochlear disorders, tinnitus and hearing-loss measurement. Cilcare names him honorary president of its scientific advisory board and describes his longstanding translational-science mentorship.

Clinical audiologist and trials manager with US clinical-practice and ENT experience. Previously monitored a Frequency Therapeutics study; now supports audiology protocols, training and auditory-signature research at Cilcare.

Cilcare is a French biotechnology company founded by Celia Belline, Sylvie Pucheu and Marie-Pierre Pasdelou to develop treatments and research technologies for auditory disorders. Its active French SAS was legally created on June 6, 2014 (SIREN 803146125; VAT FR00803146125). Based in Montpellier with operations in the Boston area and additional offices named in Paris and Tokyo, Cilcare studies cochlear synaptopathy, hearing loss, tinnitus and related conditions. It combines investigational drug candidates CIL001 and CIL003, preclinical research services and an Auditory Analytics platform using artificial intelligence and machine learning to characterize hearing function, identify biomarkers and support clinical-study patient selection. Observational studies in diabetes and neurodegenerative disease populations remain research activities; the company has not established a dementia treatment. Its public directory names 46 employees and 12 scientific advisers. An April 18, 2024 announcement confirmed an undisclosed capital infusion involving the University of Vermont Health Network, ARIS, Sofilaro and Sud PME Croissance. On December 4, 2024, Cilcare announced a EUR40 million Series A aggregate that included EUR21 million in its latest financing, naming Shionogi and SPRIM Global Investments as new investors alongside existing shareholders. Its 2017 financing included a verified EUR240,000 Sofilaro investment; the overall amount was described as more than EUR650,000. Research support includes a June 2024 EUR4.2 million France2030 i-Démo award with 40% grant support and a May 2026 FEDER project with support of up to EUR0.6 million over three years. A June 2026 Sanofi license amendment exchanged improved royalty terms for minority equity; no cash investment amount was disclosed.

Cilcare team member since 2015 with neuroscience and preclinical-development experience, including electrophysiology and intracochlear delivery. The current directory names her General Manager for Japan and Asia; its biography also describes earlier US laboratory and operational-excellence responsibilities.

Biopharmaceutical medical executive overseeing Cilcare’s medical strategy and hearing-therapy clinical development. Previously served as Chief Medical Officer at Auris Medical and has experience with public-company financing and investor relations.

Neuroscientist whose 2024 doctoral research developed an awake-animal model for tinnitus and hyperacusis with Cilcare and Institut Pasteur. Specializes in electrophysiology and tinnitus assessment using GPIAS.

Pharmacist leading Cilcare’s evidence, value and access strategy across health economics, market access and clinical outcomes. Previously worked at Sanofi in global and affiliate health-economics roles in Boston and Paris.

Auditory-neuropathy scientist leading histology and ex-vivo programs. Works on synapse analysis, electrophysiological assessment and biological sampling for preclinical hearing research.

Cilcare co-founder and CEO with a background in pharmaceutical R&D and hearing disorders. Previously led clinical-trial logistics and supply chains at Sanofi and worked on aging-related chronic-disease programs.

Pharmacology laboratory professional managing Cilcare equipment, technical operations, safety and maintenance. Supports preclinical model development, experimental methods and research data management.

Neuroscientist and audiologist specializing in hearing disorders, histology and translational research. Previously researched sensorineural hearing loss at Montpellier’s neuroscience institute and Harvard Medical School.

Preclinical study manager with expertise in in-vivo pharmacology, gene therapy, immunohistochemistry and auditory-tissue gene transfer. Supports research studies, laboratory operations and client reporting.

Preclinical research manager specializing in neurotology study planning, resources and logistics. Her responsibilities include Montpellier laboratory studies, pharmacokinetics, inner-ear surgery and local-tolerance assays.

Clinical-trial manager supporting Cilcare’s DIAMANT and SAPHIR observational studies. Previously worked for seventeen years as a surgical-unit nurse and now contributes to auditory assessments and clinical data collection.

Scientific and operations leader with research experience developing animal models of depression, Alzheimer’s disease and neuroinflammation in France and Canada. Her work connects CNS disease research with auditory drug development.

Preclinical study manager with experience in regenerative medicine, cell therapy and inflammation research at CHU Montpellier. Previously managed research projects and purchasing at a biotech company.

Life-sciences finance and digital-transformation executive responsible for Cilcare’s financing and data strategy. Previous Sanofi positions included CFO in Poland and R&D finance leadership in Asia-Pacific.

Software and medical-instrumentation engineer supporting Cilcare’s Montpellier and Boston laboratories. Develops data-acquisition, signal-processing and AI tools; previously worked on audiological systems at Echodia.

Preclinical-operations director with cell-therapy and murine-model research experience. Previously led an in-vivo model platform in Montpellier; now oversees study design, execution and reporting for Cilcare clients.

Medical-writing and program-management professional with biopharmaceutical experience. Supports research quality control, regulatory compliance and coordination among study teams and service providers.

Anesthesiologist and intensive-care physician with experience in neurosurgery, interventional neuroradiology and trauma care. Leads Cilcare translational research, observational hearing studies and auditory-biomarker validation.

Assistant project manager with training in life sciences, molecular biology, microbiology and immunology. Supports Cilcare experimental studies and holds an animal-experimentation certificate.

Preclinical scientist with experience in electrophysiology, cochlear histology and in-vitro and in-vivo experiments. Previously studied drug mechanisms for neurodegenerative and psychiatric diseases.

Cilcare marketing and communications leader responsible for brand strategy, communications material and digital initiatives. Her company biography describes more than fifteen years of professional experience.

Cilcare co-founder and compliance leader with a pharmaceutical drug-development and regulatory background. Previously directed an international regulatory department at Sanofi and worked on aging-related hearing disorders.

Preclinical program leader specializing in cochlear histology, electrophysiology and inner-ear surgery. Her earlier research investigated cellular mechanisms of drug-related and age-related hearing loss.

Clinical-operations leader with experience taking therapeutic-protein programs from preclinical research into clinical development. At Cilcare he designs development strategies for drug candidates addressing ear disorders.

Drug-development project manager with pharmaceutical, clinical-trial and preclinical program experience. Previously led pharmacology work at Galderma; now coordinates CIL001 clinical development and related regulatory and CMC activities.

Inner-ear histology scientist working at Cilcare’s Lexington, Massachusetts laboratory. Previously worked in auditory histology at Decibel Therapeutics and contributes to electrophysiology and study design.

Neuroscience drug-development professional with previous experience at Pfizer and Servier. Leads Cilcare’s early pipeline development, in-licensing, research collaborations and co-development assessment.

Preclinical hearing researcher specializing in inner-ear microsurgery and rodent and large-species studies. Previously worked at Decibel Therapeutics on efficacy, toxicity and biodistribution experiments.

Senior scientist working on preclinical auditory studies and hearing-therapy development. Previously conducted hearing-loss research at Creighton University’s Richard Bellucci Translational Hearing Center.

Neurobiology researcher and preclinical study manager experienced in murine pharmacology, stereotaxic surgery and histology. Her University of Montreal research included spinal-cord cell models and differentiation analysis.

Executive assistant to Cilcare’s COO with experience in digital strategy, IT project management and business development. Coordinates leadership schedules, communications and cross-team strategic projects.

Leads Cilcare’s US preclinical operations with expertise in electrophysiology, microsurgery, histology and in-vivo study design. Previously contributed to cancer-therapy and biosensor R&D programs.

Market-development professional connecting Cilcare research services with global clients and strategic partners. Previously led a Canadian life-sciences startup and worked in business development at CNRS.

Preclinical research scientist with molecular and cellular biology experience spanning neuroscience and gene therapy. Supports animal experiments, behavioral testing, imaging and histology for hearing research.

Research and commercial leader with academic and industrial experience in otology and CNS research. Manages Cilcare strategic alliances and CRO partnerships, supported by in-vitro and in-vivo research expertise.

Cilcare co-founder and preclinical-innovation director whose research covers tinnitus, hearing loss and in-vivo pharmacology. Previously led scientific teams at Sanofi across hearing, aging, cardiology and oncology.

Clinical-trial manager specializing in auditory electrophysiological and electroacoustic assessment. Coordinates Cilcare therapeutic studies, clinical protocols, recruitment and investigational-product supply.

Matt Walker led Shire technicaloperations after joining in2016, following engineering and supplyoperations atPfizer. He is distinct from the S2Ginvestor and UCLneurologist MatthewWalker records.

Andreas Busch is the pharmacology executive who became Shire’s R&Dhead and chiefscientificofficer inJanuary2018, following drugdiscovery leadership at Bayer. He is distinct from the youngerDanishCernelecommercefounder of the same name.

Kim Stratton led Shire’s internationalcommercial business in the pre-acquisition directory. Her previous work included internationalpharmaceutical leadership and nursing.

Perry Sternberg led Shire’s UScommercial business in the pre-acquisition directory, following pharmaceutical and ophthalmiccommercial experience. This is a historical leadership attribution.

TeiaCare develops ANCELIA, an AI and computer vision monitoring system for residential and long-term care facilities. An optical sensor above a resident’s bed monitors movement, posture and care-related conditions without requiring a wearable. A caregiver app sends alerts when attention is needed, while a manager app produces reports to support care planning, staffing and resource decisions. Its published applications include assistance with fall-risk situations, nighttime care, repositioning to address pressure-injury risk and personalized support for residents with dementia or Alzheimer’s disease. The Milan company also provides installation, staff training and ongoing implementation support.

Principal at We Venture Capital with transactional and business advisory experience. His own investor biography explicitly qualifies the Zetta board seat as prior to exit; no exact appointment or end date is supplied.

Life sciences executive whose published biography describes experience in international expansion, partnerships and product launches at SOPHiA Genetics and Foundation Medicine. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Financial and operations leader with more than twenty years of experience across large public companies and technology startups. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Leads ANCELIA’s expansion into Spain and Portugal.

Co-founded TeiaCare after family experience with residential care prompted him to develop technology supporting caregivers and residents.

Founder and architect of XetaBase and OpenCB. Published company biography identifies him as Ignacio Medina; TriNetX’s April 7, 2026 acquisition announcement supplies his full name and confirms CEO/CTO roles. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Chartered people professional focused on building technology and healthcare teams, employee experience and development. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Genomics product specialist whose earlier product roles include Congenica and Prenetics. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Head of We Venture Capital, a physician and life science investor. The investor’s published team biography identifies her Zetta observer affiliation; post-exit continuation is unverified.

Co-founder with a biomedical engineering doctorate who leads product development and customer needs at TeiaCare.

Software entrepreneur and board adviser with experience founding and scaling businesses and designing leadership strategy programs. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Clinical scientist and genomics quality specialist; former Head of Bioinformatics Quality at Genomics England, with experience implementing quality systems and IVD and ISO compliance. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Responsible for financial reporting, metrics and governance, with a focus on efficiency and digital transformation.

Life sciences commercial leader with experience in clinical trial sequencing, product strategy and European software sales. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Healthcare commercial executive and former IQVIA global lead for drug discovery and development consulting. These are roles published on Zetta’s own roster; continued appointment after the April 2026 key-assets acquisition is not independently confirmed.

Develops computer vision technology to improve ANCELIA’s monitoring capabilities.

Zetta Genomics developed XetaBase, a platform for managing and analyzing genomic and multiomic data at population scale. Built on the open-source OpenCB platform, it loads, normalizes, indexes, annotates and queries genetic variants, supporting repeated interpretation as scientific evidence changes. Healthcare organizations, researchers and life sciences companies use it for clinical and research workflows, including biomarker discovery and precision medicine. A Cambridge University and Genomics England spinout, its key assets were acquired by TriNetX on April 7, 2026; TriNetX continues supporting existing XetaBase customers and integrating the technology with its federated clinical-data network.

Bill Mordan was Shire’s pre-acquisition general counsel and companysecretary. He previously held legal roles at ReckittBenckiser and Procter&Gamble; no currentindependentShire role is implied.

Joanne Cordeiro was Shire’s pre-acquisition chief humanresources officer after joining the company in2011. The historicaldirectory records her2017 appointment and earlier technologyindustryHR experience.

Jeffrey Poulton was Shire’s CFO and executive director throughDecember31,2017. This explicitlyformer role follows his earlier companyfinance and businessunit leadership; it is not a current appointment.

Albert Stroucken, also called Al, served as a historical Shire nonexecutive director with internationalmanufacturing experience, including Owens-Illinois and H.B.Fuller.

Anne Minto served as a historical Shire nonexecutive director with legal and humanresources experience. The2017 report announced planned retirement following its2018 AGM.

Sara Mathew served as a historical Shire nonexecutive director, with finance and technologyleadership experience including Dun & Bradstreet. The role is explicitly pre-acquisition.

David Ginsburg is a physician and biomedical researcher who served as a historical Shire nonexecutive director. His published background includes hematology and genetics research at Michigan and HHMI.

Gail Fosler served as a historical Shire nonexecutive director, bringing economics and corporateadvisory experience. Her published historical role is distinct from any currentShireemployee attribution.

Ian Clark served as a historical Shire nonexecutive director following leadership at Genentech and Roche. His role here is limited to the published pre-acquisition directory.

Olivier Bohuon served on Shire’s pre-acquisition board following pharmaceutical and healthcare leadership. Its report announced a future seniorindependentdirector appointment after the2018 AGM; the planned change is qualified.

Dominic Blakemore served as a historical Shire nonexecutive director with finance and corporateleadership experience. Its report announced planned retirement following the2018 AGM; no currentShireboardclaim is made.

Thomas Dittrich was Shire’s incoming2018 CFO and executive director, following finance leadership at Sulzer and Amgen. The report’s scheduledMarch19,2018 appointment is distinguished from evidence of an actual completed appointment.

Flemming Ornskov was Shire’s pre-acquisition chief executive and a physician by training. His CEO-designate appointment inJanuary2013 preceded his actual CEO appointment inApril2013; no current independentShireCEO role is asserted.

Susan Kilsby chaired Shire before its acquisition, following senior investment-banking roles. Shire’s2017 report distinguishes her2011 board entry from her2014 chair appointment.

Shire is the historical UK-founded biopharmaceutical company founded in1986, formerly Shire plc, incorporated in Jersey and tax-resident in Ireland. Its pre-acquisition business focused on rare diseases and specialist therapies, including neuroscience and ADHD, hematology, immunology and genetic diseases. Akili’s own supporters page explicitly states that Shire Pharmaceuticals’ Strategic Investment group made a direct monetary investment in2013, separately from their collaboration on a pediatric ADHD clinical study; its check, precise date, financing stage and subscribing subsidiary are unpublished. Takeda completed the acquisition of all Shire shares on January8,2019. Shire’s independent stock listings ended; later2019 Takeda legal announcements call the subsidiary Shire Limited, formerly Shire plc. This record preserves the historical pharmaceutical buyer rather than retroactively assigning its2013 investment to Takeda or Takeda Ventures. Twenty published leaders in the2017 annual report’s early2018 board/executive directory are retained with historical and former roles, not claimed as a current independent Shire management team. Shire’s acquisitions, licensing commitments, revenue and manufacturing investments are distinct from venture-fund corpus. Actual2016 senior-note proceeds were issued by its separate financing subsidiary SAIIDAC; they are not a Shire venture fund or a duplicated parent fundraising event. Its own2017 annual report also explicitly reports an equity investment in Rani Therapeutics LLC, alongside a distinct December2017 research collaboration on oral FactorVIII delivery. The unpublished equity check is not inferred from licensing fees, options or commercial milestones; the full Rani issuer profile is queued separately.

Mecoly Dong is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Alana Green is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Amy Zhen is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

AnneMarie Bott is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Anna Bitton is published in Dimension’s current operations team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.

Frank Gao is published in Dimension’s current research team directory. Dimension invests across computing and life sciences and publishes research on biological artificial intelligence, laboratory automation and frontier science. The directory verifies this professional affiliation but does not disclose a fuller individual biography, precise seniority, employment start day or personal cash investment.